51
|
Ingen-Housz-Oro S, Milpied B, Badrignans M, Carrera C, Elshot YS, Bensaid B, Segura S, Apalla Z, Markova A, Staumont-Sallé D, Marti-Marti I, Giavedoni P, Chua SL, Darrigade AS, Dezoteux F, Starace M, Torre AC, Riganti J, de Prost N, Lebrun-Vignes B, Bauvin O, Walsh S, Ortonne N, French LE, Sibaud V. Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases. Melanoma Res 2022; 32:205-210. [PMID: 35377864 PMCID: PMC9377568 DOI: 10.1097/cmr.0000000000000819] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Among dermatologic adverse events induced by immune checkpoint inhibitors (ICI), bullous life-threatening reactions are rare. To better define the clinical and histological features, treatment, and prognosis of ICI-related severe blistering cutaneous eruptions. This retrospective case series was conducted between 2014/05/15 and 2021/04/15 by the dermatology departments of four international registries involved in drug reactions. Inclusion criteria were age ≥18 years old, skin eruption with blisters with detachment covering ≥1% body surface area and at least one mucous membrane involved, available pictures, and ICI as suspect drug. Autoimmune bullous disorders were excluded. Each participant medical team gave his own diagnosis conclusion: epidermal necrolysis (EN), severe lichenoid dermatosis (LD), or unclassified dermatosis (UD). After a standardized review of pictures, cases were reclassified by four experts in EN or LD/UD. Skin biopsies were blindly reviewed. Thirty-two patients were included. Median time to onset was 52 days (3-420 days). Cases were originally diagnosed as EN in 21 cases and LD/UD in 11 cases. After review by experts, 10/21 EN were reclassified as LD/UD. The following manifestations were more frequent or severe in EN: fever, purpuric macules, blisters, ocular involvement, and maximal detachment. Most patients were treated with topical with or without systemic corticosteroids. Eight patients (25%) died in the acute phase. The culprit ICI was not resumed in 92% of cases. In three patients, another ICI was given with a good tolerance. Histology did not reveal significant differences between groups. Severe blistering cutaneous drug reactions induced by ICI are often overdiagnosed as EN. Consensus for management is pending.
Collapse
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Dermatology department, AP-HP, Henri Mondor hospital, Créteil, France
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- Univ Paris est Créteil EpidermE, Créteil, France
- European Task Force “Dermatology for cancer patients” of EADV
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
| | - Brigitte Milpied
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- European Task Force “Dermatology for cancer patients” of EADV
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Dermatology department, CHU Bordeaux, Bordeaux, France
| | - Marine Badrignans
- Pathology department, AP-HP, Henri Mondor hospital, Créteil, France
- Université Paris Est Créteil Val de Marne UPEC, Créteil, France
| | - Cristina Carrera
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain
- CIBERER Centro de investigaciones Biomedicas en Red de Enfermedades Raras Insituto de Salud Carlos III, Spain
- Pharmacovigilance Technical Committee Hospital Clinic Barcelona, Spain
| | - Yannick S. Elshot
- European Task Force “Dermatology for cancer patients” of EADV
- Department of Dermatology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands
- Department of Dermatology, Amsterdam UMC, Univ. of Amsterdam, The Netherlands
| | - Benoit Bensaid
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- Dermatology department, CHU Edouard Herriot, Lyon, France
| | - Sonia Segura
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital del Mar, Universitat Pompeu Fabra, Barcelona, Spain
| | - Zoé Apalla
- European Task Force “Dermatology for cancer patients” of EADV
- Second Dermatology Department, Medical School, Aristotle University of Thessaloniki, Greece
| | - Alina Markova
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Dermatology, Weill Cornell Medical College, New York, NY, USA
| | - Delphine Staumont-Sallé
- FISARD group, Paris, France
- Dermatology Department, CHU Lille, University Lille, INFINITE U1286 Inserm, Lille, France
| | - Ignasi Marti-Marti
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain
| | - Priscila Giavedoni
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain
| | - Ser-Ling Chua
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Department of Dermatology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - Anne-Sophie Darrigade
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- Dermatology department, CHU Bordeaux, Bordeaux, France
| | - Frédéric Dezoteux
- FISARD group, Paris, France
- Dermatology Department, CHU Lille, University Lille, INFINITE U1286 Inserm, Lille, France
| | - Michela Starace
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology -IRCCS Policlinico di Sant’Orsola - Department of Experimental, Diagnostic and Specialty Medicine (DIMES) Alma Mater Studiorum University of Bologna, Italy
| | - Ana Clara Torre
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - Julia Riganti
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - Nicolas de Prost
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- Intensive care unit, AP-HP, Henri Mondor hospital, Créteil, France
| | - Bénédicte Lebrun-Vignes
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Regional Pharmacovigilance Center, AP-HP, Pitié-Salpêtrière hospital, Paris, France
| | - Olivia Bauvin
- FISARD group, Paris, France
- Dermatology department, CHU Charles Nicolle, Rouen, France
| | - Sarah Walsh
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Department of Dermatology, King’s College Hospital, London, United Kingdom
| | - Nicolas Ortonne
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- Pathology department, AP-HP, Henri Mondor hospital, Créteil, France
- Université Paris Est Créteil Val de Marne UPEC, Créteil, France
| | - Lars E. French
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Department of Dermatology and Allergy, University Hospital, Ludwig Maximilan University (LMU) Munich, Munich, Germany
- Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL
| | - Vincent Sibaud
- European Task Force “Dermatology for cancer patients” of EADV
- Department of Oncodermatology, Claudius Regaud Institute and University Cancer Institute Toulouse Oncopole, Toulouse, France
| |
Collapse
|
52
|
Weill A, Descamps V, Chasset F, Mahévas T, Bourgault-Villada I, Wolkenstein P, Chollet-Martin S, Ingen-Housz-Oro S, Grootenboer-Mignot S. Erythema multiforme associated with anti-plakin antibodies: a multicentric retrospective case series. J Eur Acad Dermatol Venereol 2022; 36:2438-2442. [PMID: 35607912 DOI: 10.1111/jdv.18259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 05/05/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND Erythema multiforme (EM) is a muco-cutaneous inflammatory disease mainly triggered by herpes simplex virus (HSV) recurrences. Association of EM and circulating auto-antibodies against plakins (anti-PLK-Abs [EM-PLK+]) has been reported. However, little is known about this subset of EM. OBJECTIVES We aimed to describe the clinical and immunological features and response to treatment of EM-PLK+. METHODS We conducted a retrospective multicentric study of EM-PLK+ selected from the database of the immunological laboratory of Bichat hospital, Paris, France, from January 2009 to December 2020. Anti-PLK-Abs were detected in ≥1 immunological tests: immunofluorescence assay, immunoblotting and/or ELISA. Patients with alternative diagnoses were excluded. RESULTS We included 29 patients (16 women, median age 25 [range 2-58] years). EM-PLK+ were mostly major (EM with ≥2 mucosal involvements; n = 24, 83%) and relapsing (≥2 flares; n = 23, 79%). Cutaneous lesions were target (n = 13, 54%) and target-like lesions (n = 9, 38%) with usual topography (acral, n = 19, 79%; limbs, n = 21, 88%). Mucosal lesions affected the mouth (n = 27, 96%) and genitalia (n = 19, 68%), with a median of 2 [range 0-5] mucous membranes. EM-PLK+ were suspected as certain or possible postherpetic (EM-HSV) in 19 cases (65.5%); no triggering factors were detected in 9 (31%) patients. Desmoplakin-I/II Abs were the most frequent anti-PLK-Abs (n = 20, 69%); envoplakin and periplakin Abs were detected in 11 and 9 cases. Relapsing EM-PLK+ (n = 23) were still active (≥1 flare within 6 months) in 13 (57%) patients despite immunosuppressive therapy (n = 8, 62%). Antiviral drugs were ineffective in preventing relapse in 15/16 (94%) EM-HSV. CONCLUSION The rationale for anti-PLK-Ab detection in EM is not elucidated. More systematic research of anti-PLK-Abs is warranted to better understand whether this association reflects humoral immune activity in a subset of EM or is fortuitous, related to an epitope spreading process. However, EM-PLK+ seems to be associated with major and relapsing subtypes, and difficult-to-treat cases.
Collapse
Affiliation(s)
- A Weill
- Department of Dermatology, CHU Henri Mondor, AP-HP, Créteil, France.,Referral Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Referral Center for Auto-Immune Bullous Diseases (MALIBUL), AP-HP, Paris, France
| | - V Descamps
- Department of Dermatology, CHU Bichat, AP-HP, Paris, France
| | - F Chasset
- Faculty of Medicine, Department of Dermatology, CHU Tenon, AP-HP, Sorbonne Université, Paris, France
| | - T Mahévas
- Department of Dermatology, CHU Saint-Louis, AP-HP, Paris, France
| | - I Bourgault-Villada
- Department of Dermatology, CHU Ambroise Paré, AP-HP, Boulogne Billancourt, France
| | - P Wolkenstein
- Department of Dermatology, CHU Henri Mondor, AP-HP, Créteil, France.,Referral Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Referral Center for Auto-Immune Bullous Diseases (MALIBUL), AP-HP, Paris, France.,Univ Paris Est Créteil Epiderm E, Créteil, France
| | | | - S Ingen-Housz-Oro
- Department of Dermatology, CHU Henri Mondor, AP-HP, Créteil, France.,Referral Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Referral Center for Auto-Immune Bullous Diseases (MALIBUL), AP-HP, Paris, France.,Univ Paris Est Créteil Epiderm E, Créteil, France
| | - S Grootenboer-Mignot
- Referral Center for Auto-Immune Bullous Diseases (MALIBUL), AP-HP, Paris, France.,Department of Immunobiology, CHU Bichat, AP-HP, Paris, France
| |
Collapse
|
53
|
Galadari A, Ram-Wolff C, Al Hage J, Battistella M, Vignon-Pennamen MD, Rivet J, Cayuela JM, Gabison G, Moins-Teisserenc H, Mourah S, Ingen-Housz-Oro S, Le Corre Y, Bagot M, de Masson A. Cutaneous Gamma Delta T-Cell Lymphoma with indolent evolution: A series of five cases. J Eur Acad Dermatol Venereol 2022; 36:e715-e717. [PMID: 35535450 DOI: 10.1111/jdv.18204] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Accepted: 05/03/2022] [Indexed: 12/01/2022]
Affiliation(s)
- A Galadari
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France
| | - C Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - J Al Hage
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France
| | - M Battistella
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France.,Department of Pathology, Saint-Louis Hospital, APHP, Paris, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - M D Vignon-Pennamen
- Department of Pathology, Saint-Louis Hospital, APHP, Paris, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - J Rivet
- Department of Pathology, Saint-Louis Hospital, APHP, Paris, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - J M Cayuela
- Université de Paris, Paris, France.,Laboratory of Hematology and EA3518, Saint-Louis Hospital, APHP, Paris, France
| | - G Gabison
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France
| | - H Moins-Teisserenc
- Université de Paris, Paris, France.,Laboratory of Hematology and INSERM U1160, Saint-Louis Hospital, APHP, Paris, France
| | - S Mourah
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France.,Department of Pharmacology and Tumor Genomics, Saint-Louis Hospital, Paris, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor Hospital, APHP, Créteil, France.,Univ Paris Est Créteil Epiderme, Créteil, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - Y Le Corre
- Department of Dermatology, Centre University Hospital of Angers, Angers, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - M Bagot
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - A de Masson
- Department of Dermatology, Saint-Louis Hospital, APHP, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université de Paris, Paris, France.,French Cutaneous Lymphomas Study Group, Paris, France
| |
Collapse
|
54
|
Wechsler J, Ingen-Housz-Oro S, Deschamps L, Brunet-Possenti F, Deschamps J, Delfau MH, Calderaro J, Ortonne N. Prevalence of T-cell antigen losses in mycosis fungoides and CD30-positive cutaneous T-cell lymphoproliferations in a series of 153 patients. Pathology 2022; 54:729-737. [DOI: 10.1016/j.pathol.2022.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Revised: 01/28/2022] [Accepted: 02/09/2022] [Indexed: 10/18/2022]
|
55
|
Traineau H, Benassaia E, Diaz E, Ingen-Housz-Oro S, Assier H. Allergic contact dermatitis from benzyl alcohol mimicking acute generalized exanthematous pustulosis. Contact Dermatitis 2022; 87:100-102. [PMID: 35292984 DOI: 10.1111/cod.14108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Revised: 03/05/2022] [Accepted: 03/10/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Hélène Traineau
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Erwin Benassaia
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Emmanuelle Diaz
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,Centre de référence dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Univ Paris Est Créteil EpidermE, Créteil, France
| | - Haudrey Assier
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,Centre de référence dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France
| |
Collapse
|
56
|
Guerrois F, Thibault C, Lheure C, Sohier P, Bensaid B, Ingen-Housz-Oro S, Dupin N. Life-threatening skin reaction with Enfortumab Vedotin: Six cases. Eur J Cancer 2022; 167:168-171. [DOI: 10.1016/j.ejca.2022.02.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Accepted: 02/22/2022] [Indexed: 11/26/2022]
|
57
|
Bettuzzi T, Hua C, Diaz E, Colin A, Wolkenstein P, de Prost N, Ingen-Housz-Oro S. Epidermal necrolysis: characterization of different phenotypes using an unsupervised clustering analysis. Br J Dermatol 2022; 186:1037-1039. [PMID: 35007333 DOI: 10.1111/bjd.21009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Revised: 12/07/2021] [Accepted: 01/08/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Thomas Bettuzzi
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, 94010, Créteil, France.,EpiDermE, Université Paris Est Créteil Val de Marne, 94010, Créteil, France.,Reference center for toxic bullous dermatoses and severe drug reactions TOXIBUL, Créteil, France
| | - Camille Hua
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, 94010, Créteil, France
| | - Emmanuelle Diaz
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, 94010, Créteil, France.,EpiDermE, Université Paris Est Créteil Val de Marne, 94010, Créteil, France
| | - Audrey Colin
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, 94010, Créteil, France.,Reference center for toxic bullous dermatoses and severe drug reactions TOXIBUL, Créteil, France
| | - Pierre Wolkenstein
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, 94010, Créteil, France.,Reference center for toxic bullous dermatoses and severe drug reactions TOXIBUL, Créteil, France
| | - Nicolas de Prost
- Service de réanimation médicale, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, 94010, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, 94010, Créteil, France.,EpiDermE, Université Paris Est Créteil Val de Marne, 94010, Créteil, France.,Reference center for toxic bullous dermatoses and severe drug reactions TOXIBUL, Créteil, France
| |
Collapse
|
58
|
Battesti G, Garcia C, Viguier M, Marchal V, Castel M, Joly P, Ledard AP, Konstantinou MP, Seta V, Cordel N, Duvert-Lehembre S, Tancrède-Bohin E, Belmondo T, Ingen-Housz-Oro S, d'Incan M. Real-life impact of the immunological tests to predict relapse after treatment cessation in patients with bullous pemphigoid: a French multicenter retrospective study. J Am Acad Dermatol 2022; 86:1293-1300. [DOI: 10.1016/j.jaad.2022.01.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Revised: 12/10/2021] [Accepted: 01/14/2022] [Indexed: 10/19/2022]
|
59
|
Weill A, Demeret S, Ingen-Housz-Oro S, Colin A, Bagate F, de Prost N, Weiss N. Axonal Guillain-Barré syndrome and toxic epidermal necrolysis: two cases. J Eur Acad Dermatol Venereol 2021; 36:e373-e376. [PMID: 34928508 DOI: 10.1111/jdv.17894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 11/22/2021] [Accepted: 12/16/2021] [Indexed: 11/29/2022]
Affiliation(s)
- A Weill
- Dermatology Department, Henri Mondor Hospital, AP-HP, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - S Demeret
- Neurological Intensive Care, Sorbonne Université, AP-HP, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, DMU Neurosciences, Département de Neurologie, Paris, France
| | - S Ingen-Housz-Oro
- Dermatology Department, Henri Mondor Hospital, AP-HP, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - A Colin
- Dermatology Department, Henri Mondor Hospital, AP-HP, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - F Bagate
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Intensive Care Unit, Hôpitaux Universitaires Henri Mondor, DMU MEDECINE, AP-HP, Créteil, France.,Groupe de Recherche Clinique CARMAS, Université Paris Est Créteil, Créteil, France
| | - N de Prost
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Intensive Care Unit, Hôpitaux Universitaires Henri Mondor, DMU MEDECINE, AP-HP, Créteil, France.,Groupe de Recherche Clinique CARMAS, Université Paris Est Créteil, Créteil, France
| | - N Weiss
- Neurological Intensive Care, Sorbonne Université, AP-HP, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, DMU Neurosciences, Département de Neurologie, Paris, France.,Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies Métaboliques, Biliaires et Fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.,Groupe de Recherche Clinique en Reanimation et Soins intensifs du Patient en Insuffisance Respiratoire aiguE (GRC-RESPIRE) Sorbonne Université, Paris, France
| |
Collapse
|
60
|
Mille B, Ingen-Housz-Oro S, De Prost N, Voiriot G, Soria A, Tetart F, Bernier C, Morice C, Staumont-Salle D, Dezoteux F. High frequency of eosinophilia and viral reactivation in drug hypersensitivity in patients with severe acute respiratory syndrome coronavirus 2 infection. J Eur Acad Dermatol Venereol 2021; 36:e256-e257. [PMID: 34927763 DOI: 10.1111/jdv.17885] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- B Mille
- CHU Lille, Service de Dermatologie, Lille, France
| | - S Ingen-Housz-Oro
- AP-HP, Hôpital Henri Mondor, Service de Dermatologie, Créteil, France.,Univ. Paris Est Créteil, Epiderme, Créteil, France
| | - N De Prost
- AP-HP, Hôpital Henri Mondor, Service de Réanimation, Créteil, France
| | - G Voiriot
- AP-HP, Hôpital Tenon, Sorbonne Université, Service de Médecine Intensive Réanimation, Paris, France
| | - A Soria
- AP-HP, Hôpital Tenon, Service de Dermatologie et d'Allergologie, Paris HUEP, Paris, France.,Centre d'immunologie et des Maladies Infectieuses - Paris (Cimi-Paris), INSERM U1135, Paris, France
| | - F Tetart
- CHU Rouen, Centre Erik Satie, Service de Dermatologie, Rouen, France
| | - C Bernier
- CHU Nantes, Service de Dermatologie, Nantes, France
| | - C Morice
- CHU Caen, Service de Dermatologie, Caen, France
| | - D Staumont-Salle
- CHU Lille, Service de Dermatologie, Lille, France.,Univ. Lille, CHU Lille, INSERM 1286, INFINITE - Institute for Translational Research in Inflammation, Lille, France
| | - F Dezoteux
- CHU Lille, Service de Dermatologie, Lille, France.,Univ. Lille, CHU Lille, INSERM 1286, INFINITE - Institute for Translational Research in Inflammation, Lille, France
| | | |
Collapse
|
61
|
Bettuzzi T, Ingen-Housz-Oro S, Maison P, de Prost N, Wolkenstein P, Lebrun-Vignes B, Sbidian E. Biases associated with epidermal necrolysis reporting in pharmacovigilance: An exploratory analysis using World Health Organization VigiBase. Pharmacoepidemiol Drug Saf 2021; 31:434-441. [PMID: 34907614 DOI: 10.1002/pds.5399] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Revised: 11/25/2021] [Accepted: 12/08/2021] [Indexed: 11/11/2022]
Abstract
BACKGROUND Possible biases in pharmacovigilance reporting may impact epidermal necrolysis (EN) and drugs associations. OBJECTIVES To assess biases associated with EN-reporting. METHODS Using VigiBase, the World Health Organization-pharmacovigilance database, among drugs associated with EN between 2016 and 2020, we used an unsupervised clustering including reports characteristics, that is, reporter quality, time from drug intake to EN onset, and only one suspected drug in the report. RESULTS Among 152 drugs, three clusters were identified. Cluster 1 (n = 41) exhibited drugs frequently reported within a time from intake to onset longer than 4 days, in 57 ± 13% of reports. It corresponded to well-reported drugs and was composed mainly of antivirals and antiepileptics. Cluster 2 (n = 42) exhibited drugs frequently reported within a time from drug intake to onset shorter than 4 days, in 31 ± 12% of reports. It corresponded to drugs with a high risk of protopathic bias and was composed of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and antibiotics. Cluster 3 (n = 69) exhibited drugs frequently reported with an unavailable time from drug intake to reaction, in 66 ± 11% of reports, and reported by a high frequency of consumers (9 ± 9%). It corresponded to drugs reported with a high risk of classification bias, and was composed of anticancer therapies and cardiovascular drugs. CONCLUSION Protopathic and classification biases impact EN-reporting and should be considered regarding associations with antibiotics, NSAIDs, analgesics, anticancer therapies, and cardiovascular drugs.
Collapse
Affiliation(s)
- Thomas Bettuzzi
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,EpiDermE, Univ Paris Est Créteil, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,EpiDermE, Univ Paris Est Créteil, Créteil, France.,Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves TOXIBUL, Hôpital Henri Mondor, Créteil, France
| | - Patrick Maison
- EpiDermE, Univ Paris Est Créteil, Créteil, France.,Direction Générale, ANSM, Saint-Denis, France
| | - Nicolas de Prost
- Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves TOXIBUL, Hôpital Henri Mondor, Créteil, France.,Service de Réanimation Médicale, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - Pierre Wolkenstein
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,EpiDermE, Univ Paris Est Créteil, Créteil, France.,Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves TOXIBUL, Hôpital Henri Mondor, Créteil, France
| | - Bénédicte Lebrun-Vignes
- EpiDermE, Univ Paris Est Créteil, Créteil, France.,Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves TOXIBUL, Hôpital Henri Mondor, Créteil, France.,Centre Régional de Pharmacovigilance, Service de Pharmacologie Clinique, Hôpital Pitié-Salpétrière, AP-HP, Paris, France
| | - Emilie Sbidian
- Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France.,EpiDermE, Univ Paris Est Créteil, Créteil, France.,Centre d'Investigation Clinique 1430, INSERM, Créteil, France
| |
Collapse
|
62
|
Roux C, Sbidian E, Bouaziz JD, Kottler D, Joly P, Descamps V, Prost C, Samimi M, Seneschal J, Dupin N, Girard C, Paul M, Le Cleach L, Ingen-Housz-Oro S. Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme: A Multicenter Retrospective Cohort Study. JAMA Dermatol 2021; 157:1472-1476. [PMID: 34757396 DOI: 10.1001/jamadermatol.2021.4083] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Importance Erythema multiforme (EM) may become long term, with a recurrent or persistent course. First-line treatment for chronic EM is valaciclovir. There is no consensus for selection of second-line treatment of chronic EM. Objective The aim of this study was to assess the effectiveness of treatment with thalidomide for patients with chronic EM. Design, Setting, and Participants In this retrospective national multicenter cohort study, among 68 French hospital dermatology departments contacted by e-mail, 10 reported having eligible cases. All adults aged 18 years or older under dermatology care for chronic EM (including recurrent and persistent forms) who had received thalidomide between 2010 and 2018 were included. Analyses were conducted from June 24, 2019, to December 31, 2019. Main Outcomes and Measures The primary outcome was the proportion of patients who did not experience an EM flare within 6 months of initiating thalidomide treatment for recurrent EM or with complete clearance at 6 months for persistent EM (complete remission). Results Overall, 35 patients with chronic EM (median [range] age, 33 [15-65] years; 20 [57%] female) experienced failure of at least 1 previous treatment prior to initiating treatment with thalidomide. After 6 months of continuous thalidomide treatment, 23 (66%) were in complete remission, 5 (14%) had stopped the treatment, and 7 (20%) experienced at least 1 flare. The median (IQR) initial dose followed by remission was 50 (50-100) mg/d. Main adverse effects were asthenia (16 [46%]) and neuropathy (14 [40%]). Twenty-five (71%) of patients stopped thalidomide treatment after a median (IQR) of 12 (8-20) months owing to lack of effect (7/25 [28%]), neuropathy or another adverse effect (14/25 [56%]), or long-term complete remission (4/25 [16%]). Low-dose thalidomide, less than 50 mg every other day was sufficient in 9 of 23 (39%) of responders and was associated with less neuropathy and longer treatment duration. Conclusions and Relevance In this cohort study, second-line therapy with thalidomide was associated with complete remission in two-thirds of the 35 patients with chronic EM. However, adverse events were a common cause of thalidomide withdrawal. In the long term, dose reduction when possible may allow for continuation by improving tolerance.
Collapse
Affiliation(s)
- Camille Roux
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Créteil, France
| | - Emilie Sbidian
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Créteil, France.,Université Paris Est Créteil EpiDermE, Créteil, France
| | - Jean-David Bouaziz
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Université de Paris, Paris, France
| | - Diane Kottler
- Department of Dermatology, Bichat Hospital, AP-HP, Université de Paris, Paris, France.,Department of Dermatology, Caen University Hospital, Caen, France
| | - Pascal Joly
- Department of Dermatology, Rouen University Hospital and INSERM 1234, Normandie University, Rouen, France
| | - Vincent Descamps
- Department of Dermatology, Bichat Hospital, AP-HP, Université de Paris, Paris, France.,Department of Dermatology, Caen University Hospital, Caen, France
| | - Catherine Prost
- Department of Dermatology, Avicenne Hospital, AP-HP, Bobigny, France
| | - Mahtab Samimi
- Department of Dermatology, University Hospital of Tours, Tours, France
| | - Julien Seneschal
- Department of Dermatology, National Reference Center for Rare Skin Diseases, Université Bordeaux, Bordeaux, France
| | - Nicolas Dupin
- Department of Dermatology, Cochin Hospital, AP-HP, Paris, France
| | - Céline Girard
- Department of Dermatology, Montpellier University Hospital, Montpellier, France
| | - Muriel Paul
- Université Paris Est Créteil EpiDermE, Créteil, France.,Department of Hospital Pharmacy, Henri Mondor Hospital, AP-HP, Créteil, France
| | - Laurence Le Cleach
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Créteil, France.,Université Paris Est Créteil EpiDermE, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor Hospital, AP-HP, Créteil, France.,Université Paris Est Créteil EpiDermE, Créteil, France.,Reference Center for toxic bullous dermatoses and severe drug reactions TOXIBUL, Créteil, France
| |
Collapse
|
63
|
Marcombes C, Papouin B, Ortonne N, Wemmert C, Lascaux AS, Ingen-Housz-Oro S, Bernigaud C. Syphilis has no age limit. Age Ageing 2021; 50:2270. [PMID: 34351394 DOI: 10.1093/ageing/afab161] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2021] [Revised: 05/26/2021] [Accepted: 06/23/2021] [Indexed: 11/14/2022] Open
Affiliation(s)
- Clarisse Marcombes
- Department of dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Barbara Papouin
- Department of pathology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Nicolas Ortonne
- Department of pathology, AP-HP, Henri Mondor Hospital, Créteil, France
- Faculté de Santé, Université Paris-Est Créteil, Créteil, France
| | - Charlotte Wemmert
- Department of Infectious Diseases, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Anne Sophie Lascaux
- Department of Infectious Diseases, AP-HP, Henri Mondor Hospital, Créteil, France
| | | | - Charlotte Bernigaud
- Department of dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
- Faculté de Santé, Université Paris-Est Créteil, Créteil, France
- Research group Dynamyc, EA7380, Faculté de Santé Université Paris-Est, Ecole nationale vétérinaire d’Alfort, USC ANSES, Créteil, France
| |
Collapse
|
64
|
Colboc H, Bettuzzi T, Badrignans M, Bazin D, Boury A, Letavernier E, Frochot V, Tang E, Moguelet P, Ortonne N, de Prost N, Ingen-Housz-Oro S. Calcinosis cutis in epidermal necrolysis: role of caspofungin? J Eur Acad Dermatol Venereol 2021; 36:e313-e315. [PMID: 34758165 DOI: 10.1111/jdv.17808] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- H Colboc
- Service Plaies et Cicatrisation, Sorbonne Université, Hôpital Rothschild, Paris, France.,UMR_S 1155, Sorbonne Université-UPMC Paris 06, Paris, France
| | - T Bettuzzi
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.,Univ Paris Est Créteil, EpiDermE, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - M Badrignans
- Service de Pathologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - D Bazin
- CNRS, IPC, Ba340, Université Paris XI, Orsay, France
| | - A Boury
- CNRS, IPC, Ba340, Université Paris XI, Orsay, France
| | - E Letavernier
- UMR_S 1155, Sorbonne Université-UPMC Paris 06, Paris, France.,Service des Explorations Fonctionnelles Multidisciplinaires, Sorbonne Université, Hôpital Tenon, Paris, France
| | - V Frochot
- UMR_S 1155, Sorbonne Université-UPMC Paris 06, Paris, France.,Service des Explorations Fonctionnelles Multidisciplinaires, Sorbonne Université, Hôpital Tenon, Paris, France
| | - E Tang
- UMR_S 1155, Sorbonne Université-UPMC Paris 06, Paris, France
| | - P Moguelet
- Service de Pathologie, Sorbonne Université, Hôpital Tenon, Paris, France
| | - N Ortonne
- Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| | - N de Prost
- Service de Réanimation Médicale, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - S Ingen-Housz-Oro
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.,Univ Paris Est Créteil, EpiDermE, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
| |
Collapse
|
65
|
Melin A, Chosidow O, Foulet F, Ingen-Housz-Oro S, Limal N, Audard V, Le Bras F, Botterel F, Fardet L, Bernigaud C. Don't Judge a Book by its Cover. 'Steroid Acne': an unrecognized role of Malassezia and Demodex? J Eur Acad Dermatol Venereol 2021; 36:e229-e231. [PMID: 34657328 DOI: 10.1111/jdv.17759] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Accepted: 10/15/2021] [Indexed: 11/30/2022]
Affiliation(s)
- A Melin
- Department of Dermatology, Faculté de Santé, AP-HP, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
| | - O Chosidow
- Department of Dermatology, Faculté de Santé, AP-HP, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.,EA 7380, DYNAMYC, Ecole nationale vétérinaire d'Alfort, Université Paris-Est Créteil, USC Anses, Maisons-Alfort, France
| | - F Foulet
- EA 7380, DYNAMYC, Ecole nationale vétérinaire d'Alfort, Université Paris-Est Créteil, USC Anses, Maisons-Alfort, France.,Department of Microbiology, Parasitology and Mycology, Faculté de Santé, AP-HP, Hôpital Henri Mondor, UPEC, Créteil, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, Faculté de Santé, AP-HP, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
| | - N Limal
- Department of Internal Medicine, Faculté de Santé, AP-HP, Hôpital Henri Mondor, UPEC, Créteil, France
| | - V Audard
- Department of Nephrology and Transplantation, Faculté de Santé, AP-HP, Hôpitaux Universitaires Henri Mondor, UPEC, Créteil, France.,Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Univ Paris Est Créteil, Créteil, France
| | - F Le Bras
- Lymphoid Hemopathy Unit, Faculté de Santé, AP-HP, Hôpital Henri Mondor, UPEC, Créteil, France
| | - F Botterel
- EA 7380, DYNAMYC, Ecole nationale vétérinaire d'Alfort, Université Paris-Est Créteil, USC Anses, Maisons-Alfort, France.,Department of Microbiology, Parasitology and Mycology, Faculté de Santé, AP-HP, Hôpital Henri Mondor, UPEC, Créteil, France
| | - L Fardet
- Department of Dermatology, Faculté de Santé, AP-HP, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
| | - C Bernigaud
- Department of Dermatology, Faculté de Santé, AP-HP, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.,EA 7380, DYNAMYC, Ecole nationale vétérinaire d'Alfort, Université Paris-Est Créteil, USC Anses, Maisons-Alfort, France
| |
Collapse
|
66
|
Amatore F, Ortonne N, Lopez M, Orlanducci F, Castellano R, Ingen-Housz-Oro S, De Croos A, Gorvel L, Goubard A, Bouabdallah R, Schiano JM, Bonnet N, Grob JJ, Gaulard P, Bagot M, Bensussan A, Delaporte E, Olive D. ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells. Eur J Cancer 2021; 156 Suppl 1:S23-S24. [PMID: 34649648 DOI: 10.1016/s0959-8049(21)00650-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Florent Amatore
- Centre de recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France; Department of Dermatology and Skin Cancers, Hôpital de la Timone, Aix-Marseille Université, Marseille, France; Department of Dermatology, Aix Marseille University, APHM, Hôpital Nord, Marseille, France
| | - Nicolas Ortonne
- Department of Pathology and INSERM U955 team 9, AP-HP, Hôpital Henri-Mondor, Créteil, France
| | - Marc Lopez
- Centre de recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Florence Orlanducci
- Centre de recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Rémy Castellano
- Centre de recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | | | - Amandine De Croos
- Department of Pathology and INSERM U955 team 9, AP-HP, Hôpital Henri-Mondor, Créteil, France
| | - Laurent Gorvel
- Centre de recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Armelle Goubard
- Centre de recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Réda Bouabdallah
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - Jean-Marc Schiano
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - Nathalie Bonnet
- Department of Dermatology, Aix Marseille University, APHM, Hôpital Nord, Marseille, France
| | - Jean-Jacques Grob
- Department of Dermatology and Skin Cancers, Hôpital de la Timone, Aix-Marseille Université, Marseille, France
| | - Philippe Gaulard
- Department of Pathology and INSERM U955 team 9, AP-HP, Hôpital Henri-Mondor, Créteil, France
| | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris University, Inserm, U976, Paris, France
| | - Armand Bensussan
- Paris University, INSERM, UMR-976, Institut de Recherche Saint-Louis, Paris, France
| | - Emmanuel Delaporte
- Department of Dermatology, Aix Marseille University, APHM, Hôpital Nord, Marseille, France
| | - Daniel Olive
- Centre de recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| |
Collapse
|
67
|
Decroos A, Giustiniani J, Pelletier L, Ingen-Housz-Oro S, Gaulard P, Ortonne N. PD1 in Sézary syndrome: a repressor of cell survival sometimes lost during progression, but a new target using depleting antibodies? Eur J Cancer 2021; 156 Suppl 1:S14-S15. [PMID: 34649644 DOI: 10.1016/s0959-8049(21)00652-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Amandine Decroos
- Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France
| | - Jerome Giustiniani
- Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France
| | - Laura Pelletier
- Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France
| | | | - Philippe Gaulard
- Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France; Pathology department, APHP, Henri Mondor hospital, Paris, France
| | - Nicolas Ortonne
- Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France; Pathology department, APHP, Henri Mondor hospital, Paris, France
| |
Collapse
|
68
|
Gaudin O, Milpied B, Papouin B, Hüe S, Ortonne N, Régnier E, Wolkenstein P, Chosidow O, de Prost N, Ingen-Housz-Oro S. Lupus erythematosus and epidermal necrolysis: a case series of 16 patients. Br J Dermatol 2021; 186:372-374. [PMID: 34597413 DOI: 10.1111/bjd.20775] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Revised: 09/24/2021] [Accepted: 09/26/2021] [Indexed: 01/18/2023]
Affiliation(s)
- O Gaudin
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
| | - B Milpied
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Dermatology Department, Saint André Hospital, Bordeaux, France
| | - B Papouin
- Pathology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - S Hüe
- Université Paris-Est Créteil Val de Marne, UPEC, Créteil, France.,INSERM U955, Université Paris Est Créteil Val de Marne, UPEC, Créteil, France.,Immunology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - N Ortonne
- Pathology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Université Paris-Est Créteil Val de Marne, UPEC, Créteil, France
| | - E Régnier
- Dermatology Department, AP-HP, Cochin Hospital, Paris, France
| | - P Wolkenstein
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Université Paris-Est Créteil Val de Marne, UPEC, Créteil, France
| | - O Chosidow
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Université Paris-Est Créteil Val de Marne, UPEC, Créteil, France.,Groupe de Recherche Dynamyc, EA7380, Faculté de Santé de Créteil, École Nationale Vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France
| | - N de Prost
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Université Paris-Est Créteil Val de Marne, UPEC, Créteil, France.,Intensive Care Unit, AP-HP, Henri Mondor Hospital, Créteil, France
| | - S Ingen-Housz-Oro
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,EpiDermE, Université Paris-Est Créteil, Créteil, France
| |
Collapse
|
69
|
Kridin K, Brüggen MC, Chua SL, Bygum A, Walsh S, Nägeli MC, Kucinskiene V, French L, Tétart F, Didona B, Milpied B, Ranki A, Salavastru C, Brezinová E, Divani-Patel S, Lorentzen T, Nagel JL, Valiukeviciene S, Karpaviciute V, Tiplica GS, Oppel E, Oschmann A, de Prost N, Vorobyev A, Ingen-Housz-Oro S. Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Insights From a Pan-European Multicenter Study. JAMA Dermatol 2021; 157:1182-1190. [PMID: 34431984 DOI: 10.1001/jamadermatol.2021.3154] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Importance Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe drug reactions associated with a high rate of mortality and morbidity. There is no consensus on the treatment strategy. Objective To explore treatment approaches across Europe and outcomes associated with the SJS/TEN disease course, as well as risk factors and culprit drugs. Design, Setting, and Participants A retrospective pan-European multicenter cohort study including 13 referral centers belonging to the ToxiTEN ERN-skin subgroup was conducted. A total of 212 adults with SJS/TEN were included between January 1, 2015, and December 31, 2019, and data were collected from a follow-up period of 6 weeks. Main Outcomes and Measures Risk factors for severe acute-phase complications (acute kidney failure, septicemia, and need for mechanical ventilation) and mortality 6 weeks following admission were evaluated using a multivariable-adjusted logistic regression model. One tool used in evaluation of severity was the Score of Toxic Epidermal Necrolysis (SCORTEN), which ranges from 0 to 7, with 7 the highest level of severity. Results Of 212 patients (134 of 211 [63.7%] women; mean [SD] age, 51.0 [19.3] years), the mean (SD) body surface area detachment was 27% (32.8%). In 176 (83.0%) patients, a culprit drug was identified. Antibiotics (21.2%), followed by anticonvulsants (18.9%), nonsteroidal anti-inflammatory drugs (11.8%), allopurinol (11.3%), and sulfonamides (10.4%), were the most common suspected agents. Treatment approaches ranged from best supportive care only (38.2%) to systemic glucocorticoids (35.4%), intravenous immunoglobulins (23.6%), cyclosporine (10.4%), and antitumor necrosis factor agents (3.3%). Most patients (63.7%) developed severe acute-phase complications. The 6-week mortality rate was 20.8%. Maximal body surface area detachment (≥30%) was found to be independently associated with severe acute-phase complications (fully adjusted odds ratio [OR], 2.49; 95% CI, 1.21-5.12; P = .01) and SCORTEN greater than or equal to 2 was significantly associated with mortality (fully adjusted OR, 10.30; 95% CI, 3.82-27.78; P < .001). Cyclosporine was associated with a higher frequency of greater than or equal to 20% increase in body surface area detachment in the acute phase (adjusted OR, 3.44; 95% CI, 1.12-10.52; P = .03) and an increased risk of infections (adjusted OR, 7.16; 95% CI, 1.52-33.74; P = .01). Systemic glucocorticoids and intravenous immunoglobulins were associated with a decreased risk of infections (adjusted OR, 0.40; 95% CI, 0.18-0.88; P = .02). No significant difference in 6-week mortality was found between treatment groups. Conclusions and Relevance This cohort study noted differences in treatment strategies for SJS/TEN in Europe; the findings suggest the need for prospective therapeutic studies to be conducted and registries to be developed.
Collapse
Affiliation(s)
- Khalaf Kridin
- Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.,Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
| | - Marie-Charlotte Brüggen
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.,Faculty of Medicine, University of Zurich, Zurich, Switzerland.,Medical Campus Davos, Davos, Switzerland.,ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
| | - Ser-Ling Chua
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Department of Dermatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - Anette Bygum
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Department of Dermatology and Allergy Center, Odense University Hospital, Clinical Institute, University of Southern Denmark, Odense, Denmark
| | - Sarah Walsh
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Department of Dermatology, King's College Hospital, London, United Kingdom
| | - Mirjam C Nägeli
- Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.,Faculty of Medicine, University of Zurich, Zurich, Switzerland
| | - Vesta Kucinskiene
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences (LUHS), Hospital of LUHS Kauno Klinikos, European Reference Network for Rare and Complex Diseases of the Skin members, Kaunas, Lithuania.,Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - Lars French
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany.,Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida
| | - Florence Tétart
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Toxic Bullous Dermatoses and Severe Drug Reactions reference center, TOXIBUL FIMARAD network, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,Department of Dermatology, Inserm U519, Rouen University Hospital, Rouen, France
| | - Biagio Didona
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Rare Disease Unit, I Dermatology Division, Istituto Dermopatico dell'Immacolata, IRCCS, Rome, Italy
| | - Brigitte Milpied
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Toxic Bullous Dermatoses and Severe Drug Reactions reference center, TOXIBUL FIMARAD network, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,Department of Dermatology, Saint André Hospital, Bordeaux, France
| | - Annamari Ranki
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Department of Dermatology, Allergology and Venereology, University of Helsinki, Helsinki, Finland.,Helsinki University Hospital, Inflammation Center, Helsinki, Finland
| | - Carmen Salavastru
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,Department of Pediatric Dermatology, Colentina Clinical Hospital, Bucharest, Romania
| | - Eva Brezinová
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,First Department of Dermatovenereology, Masaryk University Faculty of Medicine, St Ann's Faculty Hospital in Brno, Brno, Czech Republic
| | - Sapna Divani-Patel
- Department of Dermatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - Tine Lorentzen
- Department of Dermatology and Allergy Center, Odense University Hospital, Clinical Institute, University of Southern Denmark, Odense, Denmark
| | - Julie Loft Nagel
- Department of Dermatology and Allergy Center, Odense University Hospital, Clinical Institute, University of Southern Denmark, Odense, Denmark
| | - Skaidra Valiukeviciene
- Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences (LUHS), Hospital of LUHS Kauno Klinikos, European Reference Network for Rare and Complex Diseases of the Skin members, Kaunas, Lithuania.,Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - Viktorija Karpaviciute
- Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - George-Sorin Tiplica
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.,Department of Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Eva Oppel
- Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany
| | - Anna Oschmann
- Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany
| | - Nicolas de Prost
- Toxic Bullous Dermatoses and Severe Drug Reactions reference center, TOXIBUL FIMARAD network, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,Intensive care unit, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Artem Vorobyev
- Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.,ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Department of Dermatology, University Medical Center Schleswig-Holstein, Lübeck, Germany
| | - Saskia Ingen-Housz-Oro
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France.,Toxic Bullous Dermatoses and Severe Drug Reactions reference center, TOXIBUL FIMARAD network, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,University Paris-Est Créteil EpiDermE, Créteil, France
| |
Collapse
|
70
|
Bhujoo Z, Ingen-Housz-Oro S, Gener G, Gaudin O, Fleck M, Verlinde-Carvalho M, Paul M, Chosidow O, Wolkenstein P, Assier H. Patch tests in nonimmediate cutaneous adverse drug reactions: The importance of late readings on day 4. Contact Dermatitis 2021; 86:29-33. [PMID: 34590309 DOI: 10.1111/cod.13981] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Revised: 09/02/2021] [Accepted: 09/22/2021] [Indexed: 12/17/2022]
Abstract
BACKGROUND Patch tests (PTs) with two readings have been used for decades to identify the culprit drug in nonimmediate cutaneous adverse drug reactions (NICADRs), followed more recently by late reading of intradermal tests (IDTs). Some teams tend to perform PTs with only one reading before IDTs or even directly perform IDTs. OBJECTIVES To evaluate the relevance of a late PT reading on day 4 (D4) in NICADRs. METHODS We retrospectively selected patients who had a PT for an NICADR between July 2014 and March 2020. RESULTS During the study period, 328 patients had a PT with available results. Among the 75 positive-PT patients with available data for the two readings, 41 (54.7%) had positive results on D2 and D4 and 34 (45.3%) had negative results on D2 but positive results on D4. No patient had positive results on D2 and negative results on D4. CONCLUSION This study shows that a D4 reading enhanced the PT-positive results. A positive PT result allows for reducing the number of IDTs, which are more difficult and costly to perform. Our series suggests that a late PT reading at D4 should be performed for exploring NICADRs.
Collapse
Affiliation(s)
- Zoé Bhujoo
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France.,EA7379 EpidermE, Univ Paris Est Créteil EpidermE, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions, Créteil, France
| | - Gwendeline Gener
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions, Créteil, France
| | - Olivier Gaudin
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions, Créteil, France
| | - Margaux Fleck
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France
| | | | - Muriel Paul
- EA7379 EpidermE, Univ Paris Est Créteil EpidermE, Créteil, France.,Department of Pharmacy, AP-HP, Hôpital Henri-Mondor, Créteil, France
| | - Olivier Chosidow
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France.,University Paris Est Créteil Val de Marne UPEC, Créteil, France
| | - Paul Wolkenstein
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France.,University Paris Est Créteil Val de Marne UPEC, Créteil, France
| | - Haudrey Assier
- Dermatology Department, APHP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions, Créteil, France
| |
Collapse
|
71
|
Gaultier F, Ejeil AL, Jungo S, Ingen-Housz-Oro S, de Clatigny FLP, Bruno G, Pirnay P, Bellakhdar F, Dridi SM. Clinical relevance of interdental papilla biopsy in chronic erosive gingivitis (desquamative gingivitis): retrospective bicentric study of 148 specimens. BMC Oral Health 2021; 21:452. [PMID: 34535102 PMCID: PMC8447615 DOI: 10.1186/s12903-021-01820-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2021] [Accepted: 09/09/2021] [Indexed: 11/15/2022] Open
Abstract
Background Chronic erosive gingivitis, also called desquamative gingivitis, defines a clinical picture that can be generated by several inflammatory and immune diseases. Pathology is therefore essential for the differential diagnosis. However, when the gingival lesion is initial, exclusive or predominant, selecting the biopsy site and protocol may be problematic due to tissue fragility. Especially since there are few studies on the subject, the aim of our study was to assess the protocol, diagnostic relevance and tolerance of an original protocol using interdental papilla biopsy. Methods We conducted a retrospective bicentric study, from October 2011 to July 2019, including all patients with a chronic erosive gingivitis who had received, for diagnostic purposes, a interdental papilla biopsy. Results The contribution levels for the two hospital departments were 94.7% and 97.1%, respectively. No postoperative complication was recorded in the short or long term. Conclusion The interdental papilla biopsy protocol is perfectly adapted to the anatomopathological examinations required to establish differential diagnosis of chronic erosive gingivitis. This surgical protocol is simple to perform, non iatrogenic with a very good tolerance and and accessible to all clinicians. It is highly efficient with an excellent contribution level. ClinicalTrials NCT04293718 (March 3, 2020). Health Data Hub N° F20201109083211 (November 9, 2020). Supplementary Information The online version contains supplementary material available at 10.1186/s12903-021-01820-9.
Collapse
Affiliation(s)
- Frédérick Gaultier
- Department of Odontology, Oral Medicine and Oral Surgery, APHP Henri Mondor Hospital, Université de Paris, 1 Rue Gustave Eiffel, 94000, Créteil, France.
| | - Anne-Laure Ejeil
- Department of Odontology, Oral Medicine and Oral Surgery, Bretonneau Hospital, Université de Paris France, Paris, France
| | - Sébastien Jungo
- Department of Odontology, Oral Medicine and Oral Surgery, Bretonneau Hospital, Université de Paris France, Paris, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor Hospital, Créteil, France.,Competence Centre of Autoimmune Bullous Diseases MALIBUL, FIMARAD Sector, Créteil, France.,EA7379 EpidermE, UPEC, Créteil, France
| | | | - Gogly Bruno
- Department of Odontology, Oral Medicine and Oral Surgery, APHP Henri Mondor Hospital, Université de Paris, 1 Rue Gustave Eiffel, 94000, Créteil, France.,Laboratory of Molecular Oral Pathophysiology, INSERM 1138, Université de Paris France, Paris, France
| | - Philippe Pirnay
- Department of Odontology, Oral Medicine and Oral Surgery, APHP Henri Mondor Hospital, Université de Paris, 1 Rue Gustave Eiffel, 94000, Créteil, France
| | - Fadel Bellakhdar
- Department of Odontology, Oral Medicine and Oral Surgery, APHP Henri Mondor Hospital, Université de Paris, 1 Rue Gustave Eiffel, 94000, Créteil, France
| | - Sophie-Myriam Dridi
- Department of Odontology, Saint Roch Hospital, Nice, France.,Oral Microbiology, Immunotherapy and Health EA 7354, Nice, France
| |
Collapse
|
72
|
Lavaud J, Hüssler S, Gricourt G, de Prost N, Rodriguez C, Ingen-Housz-Oro S, Chosidow O, Bernigaud C, Woerther PL. 16S metagenomic assessment of the skin microbiota dynamic and possible association with the risk of infection in patients with epidermal necrolysis. J Eur Acad Dermatol Venereol 2021; 35:e914-e917. [PMID: 34365683 DOI: 10.1111/jdv.17584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- J Lavaud
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Faculté de Santé, Créteil, France.,EA7380 Dynamic, Faculté de Santé de Créteil, Ecole Nationale Vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France
| | - S Hüssler
- Department of Microbiology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Faculté de Santé, Créteil, France
| | - G Gricourt
- Department of Microbiology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Faculté de Santé, Créteil, France.,NGS Platform, IMRB Institute, Université Paris-Est Créteil Val-de-Marne, Créteil, France
| | - N de Prost
- Department of Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, hôpital Henri Mondor, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and severe drug reactions TOXIBUL, Créteil, France
| | - C Rodriguez
- NGS Platform, IMRB Institute, Université Paris-Est Créteil Val-de-Marne, Créteil, France.,INSERM U955, Université Paris-Est Créteil Val-de-Marne, Créteil, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Faculté de Santé, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and severe drug reactions TOXIBUL, Créteil, France.,EpiDermE, Université Paris-Est Créteil, Créteil, France
| | - O Chosidow
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Faculté de Santé, Créteil, France.,EA7380 Dynamic, Faculté de Santé de Créteil, Ecole Nationale Vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and severe drug reactions TOXIBUL, Créteil, France
| | - C Bernigaud
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Faculté de Santé, Créteil, France.,EA7380 Dynamic, Faculté de Santé de Créteil, Ecole Nationale Vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France.,Reference Center for Toxic Bullous Dermatoses and severe drug reactions TOXIBUL, Créteil, France
| | - P L Woerther
- EA7380 Dynamic, Faculté de Santé de Créteil, Ecole Nationale Vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France.,Department of Microbiology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Faculté de Santé, Créteil, France.,NGS Platform, IMRB Institute, Université Paris-Est Créteil Val-de-Marne, Créteil, France
| |
Collapse
|
73
|
Hébert V, Bastos S, Drenovska K, Meijer J, Ingen-Housz-Oro S, Bedane C, Lunardon L, Debarbieux S, Jedlickova H, Caux F, Chaby G, D'Incan M, Feliciani C, Boulard C, Schumacher N, Schmidt E, Roussel A, Richard MA, Gottlieb J, Ferranti V, Guérin O, Bénichou J, Joly P. International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg -1 per day starting dose of oral corticosteroids to treat bullous pemphigoid. Br J Dermatol 2021; 185:1232-1239. [PMID: 34173243 DOI: 10.1111/bjd.20593] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/17/2021] [Indexed: 11/28/2022]
Abstract
BACKGROUND European guidelines propose a 0·5 mg kg-1 per day dose of oral prednisone as initial treatment for bullous pemphigoid (BP). We assessed the safety and efficacy of this regimen depending on BP extent and general condition of the patients. METHODS In a prospective international study, we consecutively included all patients diagnosed with BP. Patients received a 0·5 mg kg-1 per day dose of prednisone, which was then gradually tapered 15 days after disease control, with the aim of stopping prednisone or maintaining minimal treatment (0·1 mg kg-1 per day) within 6 months after the start of treatment. The two coprimary endpoints were control of disease activity at day 21 and 1-year overall survival. Disease severity was assessed according to the Bullous Pemphigoid Disease Area Index (BPDAI) score. RESULTS In total, 198 patients were included between 2015 and 2017. The final analysis comprised 190 patients with a mean age of 80·9 (SD 9·1) years. Control of disease activity was achieved at day 21 in 119 patients [62·6%, 95% confidence interval (CI) 55·3-69.5]; 18 of 24 patients (75%, 95% CI 53·3-90·2), 75 of 110 patients (68·8%, 95% CI 59·2-77·3) and 26 of 56 patients (46.4%, 95% CI 33·0-60·3) had mild, moderate and severe BP, respectively (P = 0·0218). A total of 30 patients died during the study. The overall Kaplan-Meier 1-year survival was 82·6% (95% CI 76·3-87·4) corresponding to 90·9%, 83·0% and 80·0% rates in patients with mild, moderate and severe BP, respectively (P = 0·5). Thresholds of 49 points for BPDAI score and 70 points for Karnofsky score yielded maximal Youden index values with respect to disease control at day 21 and 1-year survival, respectively. CONCLUSIONS A 0·5 mg kg-1 per day dose of prednisone is a valuable therapeutic option in patients with mild or moderate BP whose general condition allows them to be autonomous.
Collapse
Affiliation(s)
- V Hébert
- Department of Dermatology, Rouen University Hospital, Center for Autoimmune Bullous Diseases, and INSERM U1234, Normandie University, Rouen, France
| | - S Bastos
- Department of Dermatology, Rouen University Hospital, Center for Autoimmune Bullous Diseases, and INSERM U1234, Normandie University, Rouen, France
| | - K Drenovska
- Department of Dermatology, Medical University of Sofia, Sofia, Bulgaria
| | - J Meijer
- Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands
| | - S Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor University Hospital, (AP-HP), Creteil, France
| | - C Bedane
- Department of Dermatology, Limoges University Hospital, Limoges, France
| | - L Lunardon
- Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - S Debarbieux
- Department of Dermatology, Hospices Civils de Lyon, Lyon, France
| | - H Jedlickova
- Department of Dermatology, St. Anne's Faculty Hospital, Brno, Czech Republic
| | - F Caux
- Department of Dermatology, Avicenne Hospital, University Paris 13, Bobigny, France
| | - G Chaby
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - M D'Incan
- Department of Dermatology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - C Feliciani
- Section of Dermatology, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
| | - C Boulard
- Department of Dermatology, Monod General Hospital, le Havre, France
| | - N Schumacher
- Department of Dermatology, University of Lübeck, Lübeck, Germany
| | - E Schmidt
- Department of Dermatology, University of Lübeck, Lübeck, Germany.,Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
| | - A Roussel
- Department of Dermatology, Orleans Hospital, Orléans, France
| | - M A Richard
- Department of Dermatology, Hôpital la Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - J Gottlieb
- Department of Dermatology, Saint Louis Hospital, (AP-HP), Paris, France
| | - V Ferranti
- Department of Biostatistics, Rouen University Hospital, Rouen, France
| | - O Guérin
- Department of Biostatistics, Rouen University Hospital, Rouen, France
| | - J Bénichou
- Department of Biostatistics, Rouen University Hospital, Rouen, France
| | - P Joly
- Department of Dermatology, Rouen University Hospital, Center for Autoimmune Bullous Diseases, and INSERM U1234, Normandie University, Rouen, France
| | | |
Collapse
|
74
|
Lupu J, Chosidow O, Wolkenstein P, Bergqvist C, Ortonne N, Ingen-Housz-Oro S. Pityriasis lichenoides: a clinical and pathological case series of 49 patients with an emphasis on follow-up. Clin Exp Dermatol 2021; 46:1561-1566. [PMID: 34170558 DOI: 10.1111/ced.14818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/24/2021] [Indexed: 11/30/2022]
Abstract
The classification of pityriasis lichenoides (PL) into pityriasis lichenoides et varioliformis acuta (PLEVA), PL chronica (PLC) or febrile ulceronecrotic Mucha-Habermann disease (FUMHD) mixes clinical and chronological features. In this retrospective monocentric study, we aimed to investigate the relevance of the classification in routine practice. We included 49 patients (25 women, median age 41 years). The lesions were papular in 76% of patients, necrotic in 12%, and mixed in 12%. We found three histological patterns: "classical" (65%), "lymphomatoid" (13%), and "mild" (22%). The "lymphomatoid" pattern was associated with necrotic presentation and the "mild' pattern with papular lesions (p=0.012). Among the 27 patients with follow-up, 18% had relapses and 44% a chronic form. One patient had mycosis fungoides. Neither clinical nor histological aspects were correlated with disease progression. Clinical and histological pictures reflect more the intensity of epidermal injury rather than disease course. "Pityriasis lichenoides" should be preferred to the classical PLEVA/PLC classification.
Collapse
Affiliation(s)
- J Lupu
- Department of Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - O Chosidow
- Department of Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France.,Paris Est Creteil university (UPEC), Créteil, France
| | - P Wolkenstein
- Department of Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France.,Paris Est Creteil university (UPEC), Créteil, France
| | - C Bergqvist
- Department of Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - N Ortonne
- Paris Est Creteil university (UPEC), Créteil, France.,Department of Pathology, AP-HP, Hôpital Henri Mondor, Créteil, France.,IMRB, INSERM U955 team Gaulard-Ortonne (NFL)
| | - S Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France.,Univ Paris Est Créteil EpidermE, Créteil, France
| |
Collapse
|
75
|
Giraud-Kerleroux L, Bellon N, Welfringer-Morin A, Leclerc-Mercier S, Costedoat I, Coquin J, Brun A, Roguedas-Contios AM, Bernier C, Milpied B, Tétart F, Du Thanh A, Cordel N, Bensaid B, Fargeas C, Tauber M, Renolleau S, Boralevi F, Ingen-Housz-Oro S, Bodemer C. Childhood epidermal necrolysis and erythema multiforme major: a multicentre French cohort study of 62 patients. J Eur Acad Dermatol Venereol 2021; 35:2051-2058. [PMID: 34157175 DOI: 10.1111/jdv.17469] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 06/10/2021] [Indexed: 11/30/2022]
Abstract
INTRODUCTION The distinction between epidermal necrolysis [EN; including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and overlap syndrome] and erythema multiforme major (EMM) in children is confusing. We aimed to better describe and compare these entities. MATERIALS AND METHODS This French retrospective multicentre study included children ≤18 years old referred for EN or EMM between 1 January 2008 and 1 March 2019. According to pictures, children were reclassified into TEN/overlap, SJS or EMM/unclassified (SJS/EMM) groups and compared for epidemiological and clinical data, triggers, histology and follow-up. RESULTS We included 62 children [43 boys, median age 10 years (range 3-18)]: 16 with TEN/overlap, 11 SJS and 35 EMM. The main aetiologies were drugs in EN and infections (especially Mycoplasma pneumoniae) in EMM (P < 0.001), but 35% of cases remained idiopathic (TEN/overlap, 47%; SJS, 24%; EMM, 34%). The typical target lesions predominated in EMM (P < 0.001), the trunk was more often affected in EN (P < 0.001), and the body surface area involved was more extensive in EN (P < 0.001). Mucosal involvement did not differ between the groups. Two patients with idiopathic TEN died. Histology of EMM and EN showed similar features. The recurrence rate was 42% with EMM, 7% with TEN/overlap and 0 with SJS (P < 0.001). Sequelae occurred in 75% of EN but involved 55% of EMM. CONCLUSION Clinical features of EN and EMM appeared well demarcated, with few overlapping cases. Idiopathic forms were frequent, especially for EN, meaning that a wide and thorough infectious screening, repeated if needed, is indicated for all paediatric cases of EN/EMM without any trigger drug. We propose a comprehensive panel of investigations which could be a standard work-up in such situation. Sequelae affected both EN and EMM.
Collapse
Affiliation(s)
- L Giraud-Kerleroux
- Dermatology Department, AP-HP, CHU Necker-Enfants Malades, Paris Centre University, Paris, France.,Dermatology Department, AP-HP, CHU Henri Mondor, Créteil, France
| | - N Bellon
- Dermatology Department, AP-HP, CHU Necker-Enfants Malades, Paris Centre University, Paris, France.,Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| | - A Welfringer-Morin
- Dermatology Department, AP-HP, CHU Necker-Enfants Malades, Paris Centre University, Paris, France.,Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| | - S Leclerc-Mercier
- Dermatology Department, AP-HP, CHU Necker-Enfants Malades, Paris Centre University, Paris, France.,Pathology Department, AP-HP, CHU Necker-Enfants Malades, Paris, France
| | - I Costedoat
- Dermatology Department, CHU Pellegrin-Enfants, Bordeaux, France
| | - J Coquin
- Dermatology Department, CHU Charles Nicolle, Rouen, France
| | - A Brun
- Dermatology Department, CHU Charles Nicolle, Rouen, France
| | - A-M Roguedas-Contios
- Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France.,Dermatology Department, CHRU Morvan, Brest, France
| | - C Bernier
- Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France.,Dermatology Department, CHU Hôtel-Dieu, Nantes, France
| | - B Milpied
- Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France.,Dermatology Department, CHU Pellegrin-Enfants, Bordeaux, France
| | - F Tétart
- Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France.,Dermatology Department, CHU Charles Nicolle, Rouen, France
| | - A Du Thanh
- Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France.,Dermatology Department, CHU Saint-Eloi, Montpellier, France
| | - N Cordel
- Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France.,Department of Dermatology and Clinical Immunology, Guadeloupe University Hospital, Pointe-à-Pitre, Guadeloupe.,Normandie University, UNIROUEN, IRIB, Inserm, U1234, Rouen, France
| | - B Bensaid
- Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France.,Dermatology Department, CHU Edouard Herriot, Lyon, France
| | - C Fargeas
- Dermatology Department, AP-HP, CHU Necker-Enfants Malades, Paris Centre University, Paris, France
| | - M Tauber
- Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France.,Dermatology Department, CHU Larrey, Toulouse, France
| | - S Renolleau
- Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France.,Intensive Care Unit, CHU Necker-Enfants Malades, Paris, France
| | - F Boralevi
- Dermatology Department, CHU Pellegrin-Enfants, Bordeaux, France
| | - S Ingen-Housz-Oro
- Dermatology Department, AP-HP, CHU Henri Mondor, Créteil, France.,Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France.,Univ Paris Est Creteil EpidermE, Créteil, France
| | - C Bodemer
- Dermatology Department, AP-HP, CHU Necker-Enfants Malades, Paris Centre University, Paris, France.,Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| |
Collapse
|
76
|
Skayem C, Beylot-Barry M, de Masson A, Dereure O, Ram-Wolff C, Bagot M, Vergier B, Battistella M, Ortonne N, Ingen-Housz-Oro S. Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous T-cell lymphoma: nine cases. Br J Dermatol 2021; 185:1061-1063. [PMID: 34128541 DOI: 10.1111/bjd.20580] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Revised: 06/08/2021] [Accepted: 06/13/2021] [Indexed: 12/01/2022]
Affiliation(s)
- C Skayem
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - M Beylot-Barry
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France.,INSERM U1053, Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group (GFELC), Paris, France
| | - A de Masson
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Dermatology, AP-HP, Saint-Louis Hospital, Université de Paris, INSERM U976, Paris, France
| | - O Dereure
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Dermatology, University of Montpellier and INSERM U1058 Pathogenesis and Control of Chronic Infections, Montpellier, France
| | - C Ram-Wolff
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Dermatology, AP-HP, Saint-Louis Hospital, Université de Paris, INSERM U976, Paris, France
| | - M Bagot
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Dermatology, AP-HP, Saint-Louis Hospital, Université de Paris, INSERM U976, Paris, France
| | - B Vergier
- INSERM U1053, Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Pathology, Bordeaux University Hospital, Bordeaux, France
| | - M Battistella
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Pathology, AP-HP, Saint-Louis Hospital, Université de Paris, INSERM U976, Paris, France
| | - N Ortonne
- French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,Department of Pathology, AP-HP, Henri Mondor Hospital, Créteil, France.,Paris Est Créteil University (UPEC) and IMRB, INSERM U955 Team Ortonne (NFL), Créteil, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,French Cutaneous Lymphomas Study Group (GFELC), Paris, France.,University Paris Est Créteil EpiDermE, Créteil, France
| |
Collapse
|
77
|
Monnet P, Rodriguez C, Gaudin O, Cirotteau P, Papouin B, Dereure O, Tetart F, Lalevee S, Colin A, Lebrun-Vignes B, Abe E, Alvarez JC, Demontant V, Gricourt G, de Prost N, Barau C, Chosidow O, Wolkenstein P, Hue S, Ortonne N, Milpied B, Ingen-Housz-Oro S. Towards a better understanding of adult idiopathic epidermal necrolysis: a retrospective study of 19 cases. J Eur Acad Dermatol Venereol 2021; 35:1569-1576. [PMID: 33834541 DOI: 10.1111/jdv.17274] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Accepted: 03/24/2021] [Indexed: 01/10/2023]
Abstract
BACKGROUND Most cases of Stevens-Johnson syndrome and toxic epidermal necrolysis are drug-induced. A small subset of cases remain with unknown aetiology (idiopathic epidermal necrolysis [IEN]). OBJECTIVE We sought to better describe adult IEN and understand the aetiology. METHODS This retrospective study was conducted in 4 centres of the French national reference centre for epidermal necrolysis. Clinical data were collected for the 19 adults hospitalized for IEN between January 2015 and December 2019. Wide toxicology analysis of blood samples was performed. Histology of IEN cases was compared with blinding to skin biopsies of drug-induced EN (DIEN, 'controls'). Available baseline skin biopsies were analysed by shotgun metagenomics and transcriptomics and compared to controls. RESULTS IEN cases represented 15.6% of all EN cases in these centres. The median age of patients was 38 (range 16-51) years; 68.4% were women. Overall, 63.2% (n = 12) of cases required intensive care unit admission and 15.8% (n = 3) died at the acute phase. Histology showed the same patterns of early- to late-stage EN with no difference between DIEN and IEN cases. One toxicology analysis showed unexpected traces of carbamazepine; results for other cases were negative. Metagenomics analysis revealed no unexpected pathological microorganism. Transcriptomic analysis highlighted a different pro-apoptotic pathway in IEN compared to DIEN, with an overexpression of apoptosis effectors TWEAK/TRAIL. CONCLUSIONS IEN affects young people and is a severe form of EN. A large toxicologic investigation is warranted. Different pathways seem involved in IEN and DIEN, leading to the same apoptotic effect, but the primary trigger remains unknown.
Collapse
Affiliation(s)
- P Monnet
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - C Rodriguez
- Microbiology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,INSERM U955, Université Paris Est Créteil Val de Marne, UPEC, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
| | - O Gaudin
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
| | - P Cirotteau
- Dermatology Department, Saint André Hospital, Bordeaux, France
| | - B Papouin
- Pathology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - O Dereure
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Dermatology Department, Saint Eloi Hospital, Montpellier, France
| | - F Tetart
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Dermatology Department, Charles Nicole Hospital, Rouen, France
| | - S Lalevee
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Immunology Department, INSERM, Unité U955, Institut Mondor de Recherche Biomédicale, AP-HP, Henri Mondor Hospital, Créteil, France
| | - A Colin
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
| | - B Lebrun-Vignes
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Pharmacovigilance Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - E Abe
- Pharmacology and Toxicology Department, AP-HP, Raymond Poincaré Hospital, Garches, France
| | - J-C Alvarez
- Pharmacology and Toxicology Department, AP-HP, Raymond Poincaré Hospital, Garches, France
| | - V Demontant
- Microbiology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,INSERM U955, Université Paris Est Créteil Val de Marne, UPEC, Créteil, France
| | - G Gricourt
- Microbiology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,INSERM U955, Université Paris Est Créteil Val de Marne, UPEC, Créteil, France
| | - N de Prost
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Intensive Care Unit, AP-HP, Henri Mondor Hospital, Créteil, France.,Université Paris Est Créteil Val de Marne, UPEC, Créteil, France
| | - C Barau
- Clinical Investigation Center, Henri Mondor Hospital, Créteil, France
| | - O Chosidow
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Université Paris Est Créteil Val de Marne, UPEC, Créteil, France
| | - P Wolkenstein
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Université Paris Est Créteil Val de Marne, UPEC, Créteil, France
| | - S Hue
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Immunology Department, INSERM, Unité U955, Institut Mondor de Recherche Biomédicale, AP-HP, Henri Mondor Hospital, Créteil, France.,Université Paris Est Créteil Val de Marne, UPEC, Créteil, France
| | - N Ortonne
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Pathology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Université Paris Est Créteil Val de Marne, UPEC, Créteil, France
| | - B Milpied
- Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Dermatology Department, Saint André Hospital, Bordeaux, France
| | - S Ingen-Housz-Oro
- Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France.,Univ Paris Est Créteil EpidermE, Créteil, France
| |
Collapse
|
78
|
Bergqvist C, Beylot-Barry M, Ram-Wolff C, Vergier B, Bagot M, Battistella M, Dalle S, Balme B, Merlio JP, Durupt F, Le Corre Y, Bonnet N, Le Bozec P, Skowron F, Vivard-Wallee I, Dereure O, Brunet-Possenti F, Ingen-Housz-Oro S, Ortonne N. Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group. Clin Exp Dermatol 2021; 46:1441-1451. [PMID: 33987864 DOI: 10.1111/ced.14730] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/10/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND Lymphomatoid papulosis (LyP) type D (LyP D) and type E (LyP E) have recently been described in small series of cases or isolated case reports. AIM To further describe the clinical and histological features of LyP D and E based on a retrospective multicentre study. METHODS The clinical and histopathological features of 29 patients with an initial diagnosis of LyP D or LyP E were retrospectively assessed using standardized forms. RESULTS After exclusion of 5 cases, 24 patients (14 LyP D, 10 LyP E) were enrolled in the study. The median follow-up was 2.5 years (range 1 month to 13 years). LyP D was characterized by multiple recurrent self-regressing small papules that developed central erosion or necrosis, whereas LyP E presented as papulonodular lesions that rapidly evolved into necrotic eschar-like lesions > 10 mm in size. Epidermal changes were more frequent in LyP D, whereas dermal infiltrates were deeper in LyP E. Anaplastic cytology was rare and the DUSP22 rearrangement was never observed. Two patients (8%) had an associated cutaneous lymphoma. CONCLUSION LyP D and E have distinct clinical findings and may be associated with other cutaneous lymphomas.
Collapse
Affiliation(s)
- C Bergqvist
- Department of, Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - M Beylot-Barry
- Department of, Dermatology, Bordeaux University Hospital, Bordeaux, France.,Cutaneous Lymphoma Oncogenesis Team, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - C Ram-Wolff
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - B Vergier
- Department of, Pathology, Bordeaux University Hospital, Bordeaux, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - M Bagot
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - M Battistella
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Pathology, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - S Dalle
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, University Hospital of Lyon-Sud, Lyon, France
| | - B Balme
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of, Dermatology, University Hospital of Lyon-Sud, Lyon, France.,Department of, Pathology, University Hospital of Lyon-Sud, Lyon, France
| | - J P Merlio
- Cutaneous Lymphoma Oncogenesis Team, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Bordeaux University, Bordeaux, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - F Durupt
- Department of Dermatology, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
| | - Y Le Corre
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, CHU Angers, Angers, France
| | - N Bonnet
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, Hôpitaux de Marseille, Marseille, France
| | - P Le Bozec
- Department of Dermatology, AP-HP, Hôpital Beaujon, Clichy, France
| | - F Skowron
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, Centre Hospitalier de Valence, Valence, France
| | | | - O Dereure
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, CHU de Montpellier, Montpellier, France
| | - F Brunet-Possenti
- French Cutaneous Lymphomas Study Group, Paris, France.,Department of Dermatology, AP-HP, Hôpital Bichat, Paris, France
| | - S Ingen-Housz-Oro
- Department of, Dermatology, AP-HP, Hôpital Henri Mondor, Créteil, France.,French Cutaneous Lymphomas Study Group, Paris, France
| | - N Ortonne
- Department of, Pathology, AP-HP, Hôpital Henri Mondor, Créteil, France.,French Cutaneous Lymphomas Study Group, Paris, France.,Paris Est Creteil University (UPEC) and IMRB, INSERM U955 Team Ortonne (NFL), Créteil, France
| |
Collapse
|
79
|
Bergqvist C, Bernigaud C, Ingen-Housz-Oro S, Sujobert P, Hotz C, Lebre C, Ortonne N, Chosidow O. Intravenous immunoglobulins: an eye opener on the successful treatment of severe adult-onset paraprotein-associated xanthogranulomatosis. Clin Exp Dermatol 2021; 46:1346-1348. [PMID: 33969535 DOI: 10.1111/ced.14727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Accepted: 05/06/2021] [Indexed: 11/26/2022]
Affiliation(s)
- C Bergqvist
- Departments of, Department of, Dermatology, AP-HP, Henri Mondor Jospital, Créteil, France.,Université Paris-Est Créteil, Créteil, France
| | - C Bernigaud
- Departments of, Department of, Dermatology, AP-HP, Henri Mondor Jospital, Créteil, France.,Université Paris-Est Créteil, Créteil, France
| | - S Ingen-Housz-Oro
- Departments of, Department of, Dermatology, AP-HP, Henri Mondor Jospital, Créteil, France
| | - P Sujobert
- Department of Biological Haematology, Hôpital Lyon-sud, Pierre-Bénite, France
| | - C Hotz
- Departments of, Department of, Dermatology, AP-HP, Henri Mondor Jospital, Créteil, France
| | - C Lebre
- Departments of, Department of, Dermatology, AP-HP, Henri Mondor Jospital, Créteil, France
| | - N Ortonne
- Department of, Pathology, AP-HP, Henri Mondor Jospital, Créteil, France.,Université Paris-Est Créteil, Créteil, France
| | - O Chosidow
- Departments of, Department of, Dermatology, AP-HP, Henri Mondor Jospital, Créteil, France.,Université Paris-Est Créteil, Créteil, France
| |
Collapse
|
80
|
Brüggen MC, Le ST, Walsh S, Toussi A, de Prost N, Ranki A, Didona B, Colin A, Horváth B, Brezinova E, Milpied B, Moss C, Bodemer C, Meyersburg D, Salavastru C, Tiplica GS, Howard E, Bequignon E, Bouwes Bavinck JN, Newman J, Gueudry J, Nägeli M, Zaghbib K, Pallesen K, Bygum A, Joly P, Wolkenstein P, Chua SL, Le Floch R, Shear NH, Chu CY, Hama N, Abe R, Chung WH, Shiohara T, Ardern-Jones M, Romanelli P, Phillips EJ, Stern RS, Cotliar J, Micheletti RG, Brassard A, Schulz JT, Dodiuk-Gad RP, Dominguez AR, Paller AS, Seminario-Vidal L, Mostaghimi A, Noe MH, Worswick S, Tartar D, Sheridan R, Kaffenberger BH, Shinkai K, Maverakis E, French LE, Ingen-Housz-Oro S. Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus. Br J Dermatol 2021; 185:616-626. [PMID: 33657677 DOI: 10.1111/bjd.19893] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/25/2021] [Indexed: 12/13/2022]
Abstract
BACKGROUND Supportive care is the cornerstone of management of adult and paediatric Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). However, consensus on the modalities of supportive care is lacking. OBJECTIVES Our aim in this international multicentric Delphi exercise was to establish a multidisciplinary expert consensus to standardize recommendations regarding supportive care in the acute phase of SJS/TEN. METHODS Participants were sent a survey via the online tool SurveyMonkey, consisting of 103 statements organized into 11 topics: multidisciplinary team composition, suspect drug management, infection prevention, fluid resuscitation and prevention of hypothermia, nutritional support, pain and psychological distress management, management of acute respiratory failure, local skincare, ophthalmological management, management of other mucosa, and additional measures. Participants evaluated the level of appropriateness of each statement on a scale of 1 (extremely inappropriate) to 9 (extremely appropriate). The results were analysed according to the RAND/UCLA Appropriateness Method. RESULTS Forty-five participants from 13 countries (on three continents) participated. After the first round, a consensus was obtained for 82.5% of the 103 initially proposed statements. After the second round, a final consensus was obtained for 102 statements. CONCLUSIONS We have reached an international Delphi-based consensus on best supportive care practice for SJS/TEN. Our expert consensus should help guide physicians in treating patients with SJS/TEN and thereby improve short-term prognosis and the risk of sequelae.
Collapse
Affiliation(s)
- M-C Brüggen
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.,Faculty of Medicine, University of Zurich, Zurich, Switzerland.,Christine Kühne Center for Allergy Research and Education, Davos, Switzerland.,ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France
| | - S T Le
- Department of Dermatology, University of California, Davis, Sacramento, CA, USA
| | - S Walsh
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Department of Dermatology, King's College Hospital, London, UK
| | - A Toussi
- Department of Dermatology, University of California, Davis, Sacramento, CA, USA
| | - N de Prost
- Intensive Care Unit, AP-HP, Henri Mondor Hospital, Créteil, France.,Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France
| | - A Ranki
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Department of Skin and Allergic Diseases, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | - B Didona
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,First Dermatology Division, Institute Dermopatico dell'Immacolata (I.D.I.) - IRCCS, Via Monti di Creta 104, Rome, 00167, Italy
| | - A Colin
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.,Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - B Horváth
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - E Brezinova
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Department of Dermatovenereology, St Ann's University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - B Milpied
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.,Department of Dermatology, CHU Bordeaux, Bordeaux, France
| | - C Moss
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Birmingham Children's Hospital and University of Birmingham, Birmingham, UK
| | - C Bodemer
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.,Department of Dermatology, AP-HP, Necker Hospital, Paris, France
| | - D Meyersburg
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University Salzburg, Salzburg, Austria
| | - C Salavastru
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Department of Paediatric Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - G-S Tiplica
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Department of Dermatology II, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - E Howard
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Birmingham Children's Hospital and University of Birmingham, Birmingham, UK
| | - E Bequignon
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Department of Otorhinolaryngology and Head and Neck Surgery, AP-HP, Henri Mondor Hospital, Créteil, France
| | - J N Bouwes Bavinck
- Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands
| | - J Newman
- Macmillan Skin Cancer CNS, Normanby Building, Denmark Hill, London, UK
| | - J Gueudry
- Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.,Ophthalmology Department, Hospital Charles Nicolle, EA7510, UFR Santé, Rouen University, Rouen, France
| | - M Nägeli
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
| | - K Zaghbib
- Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.,Department of Psychiatry, AP-HP, Henri Mondor-Albert Chenevier Hospitals, Cr, France
| | - K Pallesen
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Department of Dermatology, Aarhus University Hospital, Palle Juul-Jensens, Aarhus, Denmark
| | - A Bygum
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Clinical Institute, University of Southern Denmark, Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
| | - P Joly
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.,Department of Dermatology, CHU Charles, Nicolle, Rouen, France
| | - P Wolkenstein
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.,Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
| | - S-L Chua
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Queen Elizabeth Hospital Birmingham, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
| | - R Le Floch
- Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.,Réanimation Chirurgicale et des Brûlés, PTMC, CHU Nantes, Nantes, France
| | - N H Shear
- Division of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.,Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - C-Y Chu
- Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
| | - N Hama
- Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - R Abe
- Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - W-H Chung
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - T Shiohara
- Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
| | - M Ardern-Jones
- Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
| | - P Romanelli
- Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA
| | - E J Phillips
- Department of Medicine & Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - R S Stern
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | | | - R G Micheletti
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - A Brassard
- Department of Dermatology, University of California, Davis, Sacramento, CA, USA
| | - J T Schulz
- Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - R P Dodiuk-Gad
- Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - A R Dominguez
- Department of Dermatology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - A S Paller
- Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - L Seminario-Vidal
- Department of Dermatology, University of South Florida, Cutaneous Oncology Program, Moffitt Cancer Center, Tampa, FL, USA
| | - A Mostaghimi
- Department of Dermatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - M H Noe
- Department of Dermatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - S Worswick
- Keck-USC School of Medicine, Los Angeles, CA, USA
| | - D Tartar
- Department of Dermatology, University of California, Davis, Sacramento, CA, USA
| | - R Sheridan
- Burn Surgery Service, Shriners Burns Hospital, Sumner Redstone Burn Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - B H Kaffenberger
- Division of Dermatology, Department of Internal Medicine, Ohio State University, Columbus, OH, USA
| | - K Shinkai
- Department of Dermatology, University of California, San Francisco, CA, USA
| | - E Maverakis
- Department of Dermatology, University of California, Davis, Sacramento, CA, USA
| | - L E French
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.,Department of Dermatology and Allergy, University Hospital of Munich, LMU, Munich, Germany
| | - S Ingen-Housz-Oro
- ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.,Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.,Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.,Universit, EpiDermE, Créteil, France
| |
Collapse
|
81
|
Skayem C, Labonnelie A, Fardet L, Ezzedine K, Hirsch G, Ingen-Housz-Oro S, Wolkenstein P, Chosidow O, Duong TA. Which patients present to dermatologic emergencies? A survey on 1561 patients. J Eur Acad Dermatol Venereol 2021; 35:e583-e585. [PMID: 33893664 DOI: 10.1111/jdv.17298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- C Skayem
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris (APHP), Créteil, France.,Faculté de médecine, Université de Paris, Paris, France
| | - A Labonnelie
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris (APHP), Créteil, France
| | - L Fardet
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris (APHP), Créteil, France.,EA- 7379, UPEC, Créteil, France
| | - K Ezzedine
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris (APHP), Créteil, France.,EA- 7379, UPEC, Créteil, France
| | - G Hirsch
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris (APHP), Créteil, France.,Department of Dermatology, Centre Hospitalier de Marne la Vallée, Jossigny, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris (APHP), Créteil, France.,EA- 7379, UPEC, Créteil, France
| | - P Wolkenstein
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris (APHP), Créteil, France.,EA- 7379, UPEC, Créteil, France
| | - O Chosidow
- Department of Dermatology, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris (APHP), Créteil, France.,EA- 7379, UPEC, Créteil, France
| | - T A Duong
- Chaire avenir Sante numérique, équipe 8 IMRB U955, INSERM, Créteil, France.,Department of Telemedicine, Paris-Saclay University Hospitals, Assistance Publique des Hôpitaux de Paris (APHP), Boulogne-Billancourt, France
| |
Collapse
|
82
|
Braesch C, Weill A, Gaudin O, Lebrun-Vignes B, Bernigaud C, Hua C, Ortonne N, Nakad L, Chambrin V, Chosidow O, Wolkenstein P, Thomas L, Assier H, Ingen-Housz-Oro S. Relapsing generalized bullous fixed drug eruption: A severe and avoidable cutaneous drug reaction. Three case reports. Therapie 2021; 77:378-381. [PMID: 33962797 DOI: 10.1016/j.therap.2021.04.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Revised: 02/08/2021] [Accepted: 04/12/2021] [Indexed: 11/25/2022]
Affiliation(s)
- Clément Braesch
- Dermatology department, AP-HP, Henri Mondor Hospital, 51, avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France
| | - Amandine Weill
- Dermatology department, AP-HP, Henri Mondor Hospital, 51, avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France
| | - Olivier Gaudin
- Dermatology department, AP-HP, Henri Mondor Hospital, 51, avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France; Reference Center for Toxic Bullous Diseases and Severe Drug Reactions-TOXIBUL, 94000 Créteil, France.
| | - Bénédicte Lebrun-Vignes
- Regional Pharmacovigilance Center, AP-HP, Pitié-Salpêtrière Hospital, 75013 Paris, France; Department of Clinical Immunology, Antoine-Béclère Hospital, 92140 Clamart, France
| | - Charlotte Bernigaud
- Dermatology department, AP-HP, Henri Mondor Hospital, 51, avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France; Université Paris Est Créteil Val de Marne, UPEC, 94000 Créteil, France
| | - Camille Hua
- Dermatology department, AP-HP, Henri Mondor Hospital, 51, avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France
| | - Nicolas Ortonne
- Université Paris Est Créteil Val de Marne, UPEC, 94000 Créteil, France; Pathology Department, AP-HP, Henri Mondor Hospital, 94000 Créteil, France
| | - Lionel Nakad
- Emergency Department, AP-HP, Henri Mondor Hospital, 94000 Créteil, France
| | - Véronique Chambrin
- Department of Clinical Immunology, Antoine-Béclère Hospital, 92140 Clamart, France
| | - Olivier Chosidow
- Dermatology department, AP-HP, Henri Mondor Hospital, 51, avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France; Reference Center for Toxic Bullous Diseases and Severe Drug Reactions-TOXIBUL, 94000 Créteil, France; Université Paris Est Créteil Val de Marne, UPEC, 94000 Créteil, France
| | - Pierre Wolkenstein
- Dermatology department, AP-HP, Henri Mondor Hospital, 51, avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France; Reference Center for Toxic Bullous Diseases and Severe Drug Reactions-TOXIBUL, 94000 Créteil, France; Université Paris Est Créteil Val de Marne, UPEC, 94000 Créteil, France
| | - Laure Thomas
- Pharmacovigilance Center, AP-HP, Henri Mondor Hospital, 94000 Créteil, France
| | - Haudrey Assier
- Dermatology department, AP-HP, Henri Mondor Hospital, 51, avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France
| | - Saskia Ingen-Housz-Oro
- Dermatology department, AP-HP, Henri Mondor Hospital, 51, avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France; Reference Center for Toxic Bullous Diseases and Severe Drug Reactions-TOXIBUL, 94000 Créteil, France; EA 7379 EpidermE, UPEC, 94000 Créteil, France
| |
Collapse
|
83
|
Brin C, Bernigaud C, Hua C, Duong TA, Gaudin O, Colin A, de Prost N, Wolkenstein P, Chosidow O, Ingen-Housz-Oro S. Impact of systemic to topical steroids switch on the outcome of drug reaction with eosinophilia and systemic symptoms (DRESS): A monocenter retrospective study of 20 cases. Ann Dermatol Venereol 2021; 148:168-171. [PMID: 33858692 DOI: 10.1016/j.annder.2021.02.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 12/07/2020] [Accepted: 02/19/2021] [Indexed: 12/17/2022]
Abstract
BACKGROUND There is no consensus on the treatment of drug reaction with eosinophilia and systemic symptoms (DRESS). At our center, systemic steroids (SS) are used for severe cases while topical steroids (TS) are used for mild and moderate forms. OBJECTIVES To investigate the short-term outcome for patients with DRESS receiving SS as first-line therapy before being transferred to our department and then switched to TS after admission. METHODS A retrospective monocenter study in DRESS patients (RegiSCAR score≥4) transferred to our dermatology department from a different setting between 07/2012 and 06/2018 and who had received SS before being transferred. Epidemiological, clinical and laboratory data were collected, as well as details of treatment modalities and outcome. RESULTS Twenty patients were included. On admission to our department, 4 were assessed as having severe DRESS and continued on SS, while 16 were assessed as mild/moderate DRESS and were switched to TS. Among these 16 patients, the outcome on TS was favorable for 12 and quickly unfavorable for 4, who had to be switched back to SS. Retrospective analysis of the initial data (before transfer) showed that these 4 patients had previously had a greater number of severity criteria than the other 12. CONCLUSION Caution is needed not only when deciding to initiate SS in DRESS but also on withdrawal of these drugs. Our series suggests that when SS are used as first-line therapy in DRESS patients with initial severity criteria, they should not be withdrawn quickly for a switch to TS, even where progression appears favorable, due to the risk of relapse.
Collapse
Affiliation(s)
- C Brin
- Service de dermatologie, AP-HP, hôpitaux universitaires Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - C Bernigaud
- Service de dermatologie, AP-HP, hôpitaux universitaires Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Université Paris Est Créteil, EA7380 Dynamyc, EnvA, USC ANSES, rue du Général-Sarrail, 94010 Créteil cedex, France; Faculté de médecine de Créteil, université Paris-Est Créteil (UPEC), 61, avenue du Général-de-Gaulle, 94000 Créteil, France; Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - C Hua
- Service de dermatologie, AP-HP, hôpitaux universitaires Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Faculté de médecine de Créteil, université Paris-Est Créteil (UPEC), 61, avenue du Général-de-Gaulle, 94000 Créteil, France; Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - T-A Duong
- Service de dermatologie, AP-HP, hôpitaux universitaires Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - O Gaudin
- Service de dermatologie, AP-HP, hôpitaux universitaires Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - A Colin
- Service de dermatologie, AP-HP, hôpitaux universitaires Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - N de Prost
- Faculté de médecine de Créteil, université Paris-Est Créteil (UPEC), 61, avenue du Général-de-Gaulle, 94000 Créteil, France; Service de réanimation médicale, AP-HP, hôpitaux universitaires Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - P Wolkenstein
- Service de dermatologie, AP-HP, hôpitaux universitaires Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Faculté de médecine de Créteil, université Paris-Est Créteil (UPEC), 61, avenue du Général-de-Gaulle, 94000 Créteil, France; Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - O Chosidow
- Service de dermatologie, AP-HP, hôpitaux universitaires Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Faculté de médecine de Créteil, université Paris-Est Créteil (UPEC), 61, avenue du Général-de-Gaulle, 94000 Créteil, France; Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France
| | - S Ingen-Housz-Oro
- Service de dermatologie, AP-HP, hôpitaux universitaires Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Université Paris Est Créteil, EpidermE, 94010 Créteil, France; Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
| |
Collapse
|
84
|
Giraud-Kerleroux L, Bernigaud C, Droumaguet C, Thai LH, Marciano-Fellous L, Thomas L, Charpentier C, Helbert-Davidson S, Fardet L, Hüe S, Ingen-Housz-Oro S. [Purpura in a young woman with hyperthyroidism]. Rev Med Interne 2021; 42:509-512. [PMID: 33846035 DOI: 10.1016/j.revmed.2021.03.330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2020] [Revised: 02/23/2021] [Accepted: 03/21/2021] [Indexed: 10/21/2022]
Abstract
INTRODUCTION Propylthiouracil (PTU) is a synthetic antithyroid drug that can induce ANCA-associated vasculitis. OBSERVATION A 27-year-old woman diagnosed with Graves' disease was on PTU for the past 10 years. She developed purpuric lesions of the legs and on the tip of the nose diagnosed as vasculitis. ANCAs were positive, with anti-MPO and anti-PR3 on blood ELISA. After discontinuation of PTU, she was able to fully recover. CONCLUSION All synthetic antithyroid drugs can induce ANCA-associated vasculitis, more often PTU. In most cases, antibodies are directed against MPO. Dual anti-MPO and anti-PR3 positivity is possible, but rare. The mechanism could be through an accumulation of PTU in neutrophils, altering the structure of MPO and making it immunogenic. PTU can also induce ANCA-free or lupus vasculitis, maculopapular rashes or urticaria. Many other drugs can induce ANCA-associated vasculitis.
Collapse
Affiliation(s)
- L Giraud-Kerleroux
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France
| | - C Bernigaud
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France
| | - C Droumaguet
- Service d'endocrinologie, hôpital Henri-Mondor, AP-HP, Créteil, France
| | - L H Thai
- Service de médecine interne, hôpital Henri-Mondor, AP-HP, Créteil, France
| | - L Marciano-Fellous
- Service d'anatomopathologie, hôpital Henri-Mondor, AP-HP, Créteil, France
| | - L Thomas
- Centre régional de pharmacovigilance, hôpital Henri Mondor, AP-HP, Créteil, France
| | - C Charpentier
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France
| | - S Helbert-Davidson
- Service de médecine nucléaire, hôpital Henri-Mondor, AP-HP, Créteil, France
| | - L Fardet
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France
| | - S Hüe
- Laboratoire d'immunologie, hôpital Henri-Mondor, AP-HP, Créteil, France
| | - S Ingen-Housz-Oro
- Service de dermatologie, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France; UPEC, université Paris Est Créteil EpidermE, Créteil, France.
| |
Collapse
|
85
|
Gendreau S, Porcher R, Thoreau B, Paule R, Maurier F, Goulenok T, Frumholtz L, Bernigaud C, Ingen-Housz-Oro S, Mekinian A, Audemard-Verger A, Gaillet A, Perard L, Samson M, Sonneville R, Arlet JB, Mirouse A, Kahn JE, Charpentier J, Hachulla É, Hummel A, Pires T, Carron PL, Durel CA, Jourde W, Puechal X, Lega JC, Sarrot-Reynauld F, Tieulie N, Diot E, Guillevin L, Terrier B. Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract. Semin Arthritis Rheum 2021; 51:436-441. [PMID: 33711774 DOI: 10.1016/j.semarthrit.2021.03.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Revised: 02/04/2021] [Accepted: 03/01/2021] [Indexed: 01/13/2023]
Abstract
BACKGROUND Gastrointestinal (GI) involvement was described to be a poor prognostic factor in systemic necrotizing vasculitis. Its prognostic significance may vary according to clinical presentation and vasculitis subtype. AIMS This study investigated risk-factors associated to poor outcome in GI-involvement of vasculitis. METHODS Patients with systemic vasculitis as defined by the 2012 Chapel Hill Consensus Conference and presenting with GI involvement were retrospectively included. Baseline characteristics, treatments and outcome were recorded. Primary endpoint was a composite of admission to intensive care unit (ICU), emergency surgical procedure, or death. RESULTS Two hundred and thirteen patients were included. Vasculitis were distributed as follows: 41% IgA vasculitis, 27% ANCA-associated vasculitis, 17% polyarteritis nodosa (PAN), and 15% other vasculitis. Eighty-three (39%) patients fulfilled the composite primary endpoint within 6 months. Predictive factors associated with the primary endpoint included PAN subtype (OR 3.08, 95% CI 1.29-7.34), performance status (OR 1.40, 1.05-1.87), use of morphine (OR 2.51, 0.87-7.24), abdominal guarding (OR 3.08, 1.01-9.37), ileus (OR 2.29, 0.98-5.32), melena (OR 2.74, 1.17-6.42), increased leukocytes (per G/L, OR 1.05, 1.00-1.10), low hemoglobin (per g/dL, OR 0.80, 0.71-0.91) and increased CRP (log mg/L, OR 1.21, 0.94-1.56). A risk prediction model for the achievement of primary endpoint had a very good performance [C-statistics 0.853 (0.810 to 0.895], and for overall survival as well. CONCLUSIONS Vasculitis presenting with GI involvement have a poor outcome in more than one third of cases. An easy-to-use risk prediction model had a very good performance to predict the admission to ICU, emergency surgical procedure, or death.
Collapse
Affiliation(s)
- Ségolène Gendreau
- Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
| | - Raphael Porcher
- Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité, Hôtel-Dieu, Paris, France
| | - Benjamin Thoreau
- Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
| | - Romain Paule
- Department of Internal Medicine, Hôpital Foch, Suresnes, France
| | - François Maurier
- Department of Internal Medicine, Hôpital Sainte-Blandine De Metz, Metz, France
| | - Tiphaine Goulenok
- Department of Internal Medicine, Hôpital Bichat - Claude-Bernard, AP-HP, Paris, France
| | - Laure Frumholtz
- Department of Dermatology, Hôpital Saint-Louis, AP-HP, Paris, France
| | | | | | - Arsène Mekinian
- Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France
| | | | - Antoine Gaillet
- Intensive-care unit, Hôpital Bichat-Claude-Bernard, AP-HP, Paris, France
| | - Laurent Perard
- Department of Internal Medicine, Centre Hospitalier Saint Joseph Saint Luc, Lyon, France
| | - Maxime Samson
- Department of Clinical Immunology and Internal Medicine, CHU de Dijon, Dijon, France
| | - Romain Sonneville
- Intensive-care unit, Hôpital Bichat-Claude-Bernard, AP-HP, Paris, France
| | - Jean-Benoît Arlet
- Department of Internal Medicine, Hôpital européen Georges Pompidou, AP-HP, Paris, France
| | | | - Jean-Emmanuel Kahn
- Department of Internal Medicine, Hôpital Ambroise Paré, AP-HP, Boulogne, France
| | | | - Éric Hachulla
- Department of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, Lille, France
| | - Aurélie Hummel
- Department of Nephrology, Hôpital Necker, AP-HP, Paris, France
| | - Thomas Pires
- Department of Internal Medicine, CHU Bordeaux, Bordeaux, France
| | | | - Cécile-Audrey Durel
- Department of Internal Medicine, Hôpital Edouard Herriot, CHU Lyon, Lyon, France
| | - Wendy Jourde
- Department of Internal Medicine, CHU Bordeaux, Bordeaux, France
| | - Xavier Puechal
- Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
| | - Jean-Christophe Lega
- Department of Internal Medicine, Hôpital Edouard Herriot, CHU Lyon, Lyon, France
| | | | | | - Elisabeth Diot
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, Tours, France
| | - Loïc Guillevin
- Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
| | - Benjamin Terrier
- Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France.
| | | |
Collapse
|
86
|
Jaouen F, Tessier MH, Vaillant L, Azib-Meftah S, Misery L, Bénéton N, Delaporte E, Kaddour A, Ingen-Housz-Oro S, Nahon S, Masson-Regnault M, Sibaud V, Fricain JC, Bessis D, Girard C, Samimi M. Response to systemic therapies in granulomatous cheilitis: Retrospective multicenter series of 61 patients. J Am Acad Dermatol 2021; 86:667-669. [PMID: 33621604 DOI: 10.1016/j.jaad.2021.02.047] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2021] [Revised: 02/11/2021] [Accepted: 02/14/2021] [Indexed: 01/17/2023]
Affiliation(s)
- Frédéric Jaouen
- Université François Rabelais, Tours, France; Dermatology Department, CHU Tours, Tours, France
| | - Marie-Hélène Tessier
- CHU Nantes, Dermatology Department and Maxillofacial Surgery Department, Nantes, France
| | - Loic Vaillant
- Université François Rabelais, Tours, France; Dermatology Department, CHU Tours, Tours, France
| | | | | | | | | | - Amina Kaddour
- Oral Pathology and Surgery Department, CHU Mustapha, Sidi M'Hamed, Algeria
| | | | - Stéphane Nahon
- Gastroenterology Department, Le Raincy Montfermeil Hospital, Montfermeil, France
| | | | | | | | - Didier Bessis
- Dermatology Department, CHU Montpellier, Montpellier, France
| | - Celine Girard
- Dermatology Department, CHU Montpellier, Montpellier, France
| | - Mahtab Samimi
- Université François Rabelais, Tours, France; Dermatology Department, CHU Tours, Tours, France.
| |
Collapse
|
87
|
Mignard C, Maho-Vaillant M, Golinski ML, Balayé P, Prost-Squarcioni C, Houivet E, Calbo SB, Labeille B, Picard-Dahan C, Konstantinou MP, Chaby G, Richard MA, Bouaziz JD, Duvert-Lehembre S, Delaporte E, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bédane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Joly P, Hébert V. Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Dermatol 2020; 156:545-552. [PMID: 32186656 DOI: 10.1001/jamadermatol.2020.0290] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Importance Rituximab and short-term corticosteroid therapy are the criterion standard treatments for patients with newly diagnosed moderate to severe pemphigus. Objective To examine factors associated with short-term relapse in patients with pemphigus treated with rituximab. Design, Setting, and Participants This post hoc analysis of a randomized clinical trial (Comparison Between Rituximab Treatment and Oral Corticosteroid Treatment in Patients With Pemphigus [RITUX 3]) conducted from January 1, 2010, to December 31, 2015, included patients from 20 dermatology departments of tertiary care centers in France from the RITUX 3 trial and 3 newly diagnosed patients treated according to the trial protocol. Data analysis was performed from February 1 to June 30, 2019. Exposure Patients randomly assigned to the rituximab group in the RITUX 3 trial and the 3 additional patients were treated with 1000 mg of intravenous rituximab on days 0 and 14 and 500 mg at months 12 and 18 combined with a short-term prednisone regimen. Main Outcomes and Measures Baseline (pretreatment) clinical and biological characteristics (Pemphigus Disease Area Index [PDAI] score, ranging from 0-250 points, with higher values indicating more severe disease) and changes in anti-desmoglein (DSG) 1 and anti-DSG3 values as measured by enzyme-linked immunosorbent assay during the 3 months after rituximab treatment were compared between patients with disease relapse and those who maintained clinical remission during the first 12 months after treatment. The positive and negative predictive values of these factors were calculated. Results Among 47 patients (mean [SD] age, 54.3 [17.0] years; 17 [36%] male and 30 [64%] female) included in the study, the mean (SD) baseline PDAI score for patients with relapsing disease was higher than that of the patients with nonrelapsing disease (54 [33] vs 28 [24]; P = .03). At month 3, 7 of 11 patients with relapsing disease (64%) vs 7 of 36 patients with nonrelapsing disease (19%) had persistent anti-DSG1 antibody values of 20 IU/mL or higher and/or anti-DSG3 antibody values of 130 IU/mL or higher (P = .01). A PDAI score of 45 or higher defining severe pemphigus and/or persistent anti-DSG1 antibody values of 20 IU/mL or higher and/or anti-DSG3 antibody values of 130 IU/mL or higher at month 3 provided a positive predictive value of 50% (95% CI, 27%-73%) and a negative predictive value of 94% (95% CI, 73%-100%) for the occurrence of relapse after rituximab. Conclusions and Relevance The findings suggest that initial PDAI score and changes in anti-DSG antibody values after the initial cycle of rituximab might help differentiate a subgroup of patients with high risk of relapse who might benefit from maintenance rituximab infusion at month 6 from a subgroup of patients with low risk of relapse who do not need early maintenance therapy. Trial Registration NCT00784589.
Collapse
Affiliation(s)
- Claire Mignard
- Centre de référence des maladies bulleuses auto-immunes, Department of Dermatology, Rouen University Hospital, Normandie University, INSERM U1234, Rouen, France
| | - Maud Maho-Vaillant
- Centre de référence des maladies bulleuses auto-immunes, Department of Dermatology, Rouen University Hospital, Normandie University, INSERM U1234, Rouen, France
| | - Marie-Laure Golinski
- Centre de référence des maladies bulleuses auto-immunes, Department of Dermatology, Rouen University Hospital, Normandie University, INSERM U1234, Rouen, France
| | - Pierre Balayé
- Department of Biostatistics and Clinical Research, Rouen University Hospital, Rouen, France
| | - Catherine Prost-Squarcioni
- Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Department of Dermatology, University of Paris 13, Bobigny, France
| | - Estelle Houivet
- Department of Biostatistics and Clinical Research, Rouen University Hospital, Rouen, France
| | - Sé Bastien Calbo
- Centre de référence des maladies bulleuses auto-immunes, Department of Dermatology, Rouen University Hospital, Normandie University, INSERM U1234, Rouen, France
| | - Bruno Labeille
- Department of Dermatology, University of Saint Etienne, Saint Etienne, France
| | | | | | - Guillaume Chaby
- Department of Dermatology, University of Amiens, Amiens, France
| | - Marie-Aleth Richard
- Assistance Publique des Hôpitaux de Marseille, Department of Dermatology, Aix Marseille University, UMR 911, INSERM CRO2, Marseille, France
| | - Jean-David Bouaziz
- Department of Dermatology, St Louis Hospital, Paris 7 Sorbonne Paris Cité University, Paris, France
| | | | | | | | - Frédéric Caux
- Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Department of Dermatology, University of Paris 13, Bobigny, France
| | - Marina Alexandre
- Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Department of Dermatology, University of Paris 13, Bobigny, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - Pierre Vabres
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - Gaëlle Quereux
- Department of Dermatology, University of Nantes, Nantes, France
| | - Alain Dupuy
- Department of Dermatology, University of Rennes, Rennes, France
| | - Sébastien Debarbieux
- Department of Dermatology, Centre Hospitalier Lyon Sud, Pierre Bénite, Lyon, France
| | | | - Michel D'Incan
- Department of Dermatology, University of Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Nathalie Bénéton
- Department of Dermatology, Le Mans General Hospital, Le Mans, France
| | - Denis Jullien
- Department of Dermatology, Edouard Herriot Hospital, Lyon Claude Bernard University, Lyon, France
| | - Nicolas Dupin
- Department of Dermatology, University of Paris V, Paris, France
| | - Laurent Misery
- Department of Dermatology, Brest University Hospital, Brest, France
| | - Laurent Machet
- Department of Dermatology, Tours University Hospital, Tours, France
| | | | - Olivier Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - Bruno Sassolas
- Department of Internal Medicine, Brest University Hospital, Brest, France
| | - Jacques Benichou
- Department of Biostatistics and Clinical Research, Rouen University Hospital, Rouen, France
| | - Pascal Joly
- Centre de référence des maladies bulleuses auto-immunes, Department of Dermatology, Rouen University Hospital, Normandie University, INSERM U1234, Rouen, France
| | - Vivien Hébert
- Centre de référence des maladies bulleuses auto-immunes, Department of Dermatology, Rouen University Hospital, Normandie University, INSERM U1234, Rouen, France
| | | |
Collapse
|
88
|
Decroos A, Giustiniani J, Pelletier L, Ingen-Housz-Oro S, Gaulard P, Ortonne N. PD1 dans le syndrome de Sézary : un répresseur de la survie cellulaire parfois perdu lors de la progression tumorale mais une nouvelle cible thérapeutique par approche déplétante ? Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
89
|
Dobos G, de Masson A, Ram-Wolff C, Beylot-Barry M, Pham-Ledard A, Ortonne N, Ingen-Housz-Oro S, Battistella M, d'Incan M, Rouanet J, Franck F, Vignon-Pennamen MD, Franck N, Carlotti A, Boulinguez S, Lamant L, Petrella T, Dalac S, Joly P, Courville P, Rivet J, Dereure O, Amatore F, Taix S, Grange F, Durlach A, Quéreux G, Josselin N, Moulonguet I, Mortier L, Dubois R, Maubec E, Laroche L, Michel L, Templier I, Barete S, Nardin C, Augereau O, Vergier B, Bagot M. Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry. Br J Dermatol 2020; 184:1059-1067. [PMID: 33131055 DOI: 10.1111/bjd.19644] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/28/2020] [Indexed: 12/16/2022]
Abstract
BACKGROUND Primary cutaneous lymphomas (PCLs) are a heterogeneous group of T-cell (CTCL) and B-cell (CBCL) malignancies. Little is known about their epidemiology at initial presentation in Europe and about potential changes over time. OBJECTIVES The aim of this retrospective study was to analyse the frequency of PCLs in the French Cutaneous Lymphoma Registry (GFELC) and to describe the demography of patients. METHODS Patients with a centrally validated diagnosis of primary PCL, diagnosed between 2005 and 2019, were included. RESULTS The calculated incidence was unprecedently high at 1·06 per 100 000 person-years. The number of included patients increased yearly. Most PCL subtypes were more frequent in male patients, diagnosed at a median age of 60 years. The relative frequency of rare CTCL remained stable, the proportion of classical mycosis fungoides (MF) decreased, and the frequency of its variants (e.g. folliculotropic MF) increased. Similar patterns were observed for CBCL; for example, the proportion of marginal-zone CBCL increased over time. CONCLUSIONS Changes in PCL frequencies may be explained by the emergence of new diagnostic criteria and better description of the entities in the most recent PCL classification. Moreover, we propose that an algorithm should be developed to confirm the diagnosis of PCL by central validation of the cases.
Collapse
Affiliation(s)
- G Dobos
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | - A de Masson
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | - C Ram-Wolff
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | - M Beylot-Barry
- Dermatology Department, Université de Bordeaux, Bordeaux, France
| | - A Pham-Ledard
- Dermatology Department, Université de Bordeaux, Bordeaux, France
| | - N Ortonne
- Pathology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France
| | - S Ingen-Housz-Oro
- Dermatology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France
| | - M Battistella
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France.,Pathology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - M d'Incan
- Dermatology and Cutaneous Oncology, Estaing University Hospital, Université de Clermont-Ferrand, Clermont-Ferrand, France
| | - J Rouanet
- Pathology Department, NHE Clermont et SIPATH UNILABS, Clermont-Ferrand, France
| | - F Franck
- Pathology Department, NHE Clermont et SIPATH UNILABS, Clermont-Ferrand, France
| | | | - N Franck
- Dermatology Department, Cochin Hospital, AP-HP, Paris, France
| | - A Carlotti
- Pathology Department, Cochin Hospital, AP-HP, Paris, France
| | - S Boulinguez
- Dermatology Department, Cahors Hospital, Toulouse, France
| | - L Lamant
- Pathology and Cytopathology Department, Institut Universitaire du Cancer Toulouse, Toulouse, France
| | - T Petrella
- Pathology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - S Dalac
- Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - P Joly
- Dermatology Department, Rouen University Hospital, INSERM U1234, Rouen Institute for Research and Innovation in Biomedicine, Rouen, France
| | - P Courville
- Pathology Department, Rouen University Hospital, INSERM U1234, Rouen Institute for Research and Innovation in Biomedicine, Rouen, France
| | - J Rivet
- Dermatology Department, Université de Bordeaux, Bordeaux, France.,Pathology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France
| | - O Dereure
- Dermatology Department, Montpellier University Hospital, Montpellier, France
| | - F Amatore
- Department of Dermatology and Oncodermatology, Aix-Marseille University, AP-HM, Timone Hospital, Marseille, France
| | - S Taix
- Department of Pathology, Aix-Marseille University, AP-HM, Timone Hospital, Marseille, France
| | - F Grange
- Dermatology Department, Robert Debré University Hospital, Reims, France
| | - A Durlach
- Pathology Department, Reims University Hospital, Reims, France
| | - G Quéreux
- Dermatology Department, Nantes University Hospital, Nantes, France
| | - N Josselin
- Pathology Department, Nantes University Hospital, Nantes, France
| | - I Moulonguet
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - L Mortier
- Dermatology Department, Claude Huriez University Hospital, INSERM U1189, Université de Lille, Lille, France
| | - R Dubois
- Pathology Department, Claude Huriez University Hospital, Lille, France
| | - E Maubec
- Dermatology Department, Avicenne Hospital, AP-HP, Paris, France
| | - L Laroche
- Dermatology Department, Avicenne Hospital, AP-HP, Paris, France
| | - L Michel
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | - I Templier
- Dermatology Department, Grenoble University Hospital, Grenoble, France
| | - S Barete
- Dermatology Department, Pité-Salpêtrière Hospital, AP-HP, Paris, France
| | - C Nardin
- Dermatology Department, Minjoz Hospital, Besancon, France, INSERM U1098, University of Franche Comté, EFS Bourgogne Franche-Comté and Franche-Comté University, Besançon, France
| | - O Augereau
- Pathology Department, Saint-André Hospital, Bordeaux University Hospital, INSERM U1053 - UMR BaRITOn, Eq 3 Oncogenèse des Lymphomes Cutanés, Université de Bordeaux, Bordeaux, France
| | - B Vergier
- Pathology Department, Saint-André Hospital, Bordeaux University Hospital, INSERM U1053 - UMR BaRITOn, Eq 3 Oncogenèse des Lymphomes Cutanés, Université de Bordeaux, Bordeaux, France
| | - M Bagot
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | | |
Collapse
|
90
|
Assier H, Gener G, Chosidow O, Wolkenstein P, Ingen-Housz-Oro S. Acute generalized exanthematous pustulosis induced by enoxaparin: 2 cases. Contact Dermatitis 2020; 84:280-282. [PMID: 33131094 DOI: 10.1111/cod.13734] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Revised: 10/23/2020] [Accepted: 10/27/2020] [Indexed: 11/30/2022]
Affiliation(s)
- Haudrey Assier
- Department of Dermatology, Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| | - Gwendeline Gener
- Department of Dermatology, Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| | - Olivier Chosidow
- Department of Dermatology, Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| | - Pierre Wolkenstein
- Department of Dermatology, Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Reference Centre for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, AP-HP, Hôpital Henri-Mondor, UPEC, Créteil, France
| |
Collapse
|
91
|
Briand C, Gourier G, Poizeau F, Jelti L, Bachelerie M, Quéreux G, Jeudy G, Acquitter M, Ingen-Housz-Oro S, Caux F, Prost C, Darrigade AS, Heron Mermin D, Mahé E, Picart Dahan C, Richard MA, Clerc CJ, Salle De Chou C, Plée J, Abasq-Thomas C, Misery L, Brenaut E. Characteristics of Pruritus in Bullous Pemphigoid and Impact on Quality of Life: A Prospective Cohort Study. Acta Derm Venereol 2020; 100:adv00320. [PMID: 33135772 PMCID: PMC9309871 DOI: 10.2340/00015555-3683] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Pruritus is a common symptom of bullous pemphigoid (BP), but has been poorly studied. The aim of this study was to analyse the characteristics of pruritus in patients with BP and its impact on their quality of life. A multicentre prospective observational study (in 15 French hospitals) was performed. A total of 60 patients were included, with a mean age of 77.4 years. Pruritus occurred daily in 85% of patients, with a mean pruritus intensity of 5.2/10. Tingling sensations were present in 72.4% of patients and burning sensations in 68.9%. Pruritus was exacerbated by stress, fatigue and xerosis. The mean ItchyQol score was 56.2/110 and the mean 5-D Itch Scale score was 16.5/25. The severity of pruritus was not related to age, sex, BP activity score, eosinophilia, or anti-BP230 and anti-BP180 autoantibodies. This study revealed that pruritus in BP is poorly tolerated and is an important cause of impaired quality of life.
Collapse
Affiliation(s)
- Clémence Briand
- Department of Dermatology, Centre Hospitalier Universitaire (CHU) Brest, FR-29609 Brest, France. E-mail:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
92
|
Amatore F, Ortonne N, Lopez M, Ingen-Housz-Oro S, Grob J, Gaulard P, Bagot M, Bensussan A, Berbis P, Olive D. ICOS est fortement exprimé dans les lymphomes T cutanés épidermotropes et son ciblage permet l’inhibition des cellules tumorales. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.08.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
93
|
Amatore F, Ortonne N, Lopez M, Orlanducci F, Castellano R, Ingen-Housz-Oro S, De Croos A, Salvado C, Gorvel L, Goubard A, Collette Y, Bouabdallah R, Schiano JM, Bonnet N, Grob JJ, Gaulard P, Bagot M, Bensussan A, Berbis P, Olive D. ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. Blood Adv 2020; 4:5203-5214. [PMID: 33095875 PMCID: PMC7594390 DOI: 10.1182/bloodadvances.2020002395] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Accepted: 08/20/2020] [Indexed: 02/06/2023] Open
Abstract
The treatment of advanced-stage cutaneous T-cell lymphoma (CTCL) remains an unmet medical need. Mogamulizumab, anti-KIR3DL2, and brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate (ADC) coupled with monomethyl-auristatin-E (MMAE), provided encouraging results, but new targeted therapies are needed. Inducible T-cell costimulator (ICOS), a T-cell costimulatory receptor, is a promising therapeutic target, not only because it is expressed by malignant T cells in CTCL but also because of its connection with the suppressive activity of regulatory T (Treg) cells. Immunohistochemical analysis revealed that ICOS was widely expressed by malignant cells in skin biopsy specimens from 52 patients with mycosis fungoides and Sézary syndrome (SS), as well as in involved node biopsy specimens from patients with SS. Furthermore, flow cytometry demonstrated its strong expression by circulating tumor cells in all our patients with SS. Percentages of ICOS+ Treg cells were significantly higher in patients with SS than in healthy donors. We then investigated the preclinical efficacy of anti-ICOS ADCs generated by coupling murine anti-ICOS monoclonal antibodies with MMAE and pyrrolobenzodiazepine. In 3 CTCL cell lines (Myla, MJ, and HUT78), we observed a significant dose-dependent decrease in cell viability in the presence of anti-ICOS ADCs. In addition, anti-ICOS-MMAE ADCs had an in vitro and in vivo efficacy superior to BV in a mouse xenograft model (MyLa). Finally, we assessed the efficacy of anti-ICOS ADCs in ICOS+ patient-derived xenografts from patients with SS and angioimmunoblastic T-cell lymphoma. Collectively, our findings provide the preliminary basis for a therapeutic trial.
Collapse
Affiliation(s)
- Florent Amatore
- Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Centre National de la Recherche Scientifique U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
- Department of Dermatology and Skin Cancers, Hôpital de la Timone, Aix Marseille Université, Marseille, France
- Department of Dermatology, Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France
| | | | - Marc Lopez
- Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Centre National de la Recherche Scientifique U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Florence Orlanducci
- Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Centre National de la Recherche Scientifique U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Rémy Castellano
- Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Centre National de la Recherche Scientifique U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Créteil, France
| | | | | | - Laurent Gorvel
- Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Centre National de la Recherche Scientifique U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Armelle Goubard
- Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Centre National de la Recherche Scientifique U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Yves Collette
- Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Centre National de la Recherche Scientifique U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| | - Réda Bouabdallah
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Jean-Marc Schiano
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Nathalie Bonnet
- Department of Dermatology, Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France
| | - Jean-Jacques Grob
- Department of Dermatology and Skin Cancers, Hôpital de la Timone, Aix Marseille Université, Marseille, France
| | | | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris University, INSERM U976, Paris, France; and
| | - Armand Bensussan
- Paris University, INSERM, UMR-976, Institut de Recherche Saint-Louis, Paris, France
| | - Philippe Berbis
- Department of Dermatology, Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France
| | - Daniel Olive
- Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Centre National de la Recherche Scientifique U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
| |
Collapse
|
94
|
Giraud-Kerleroux L, Charpentier C, Bernigaud C, Ortonne N, Hua C, Gaudron S, Nguyen QTR, Chosidow O, Wolkenstein P, Ingen-Housz-Oro S. Missed Diagnosis of Epilepsy-Associated Scald Burns: Two Cases Initially Diagnosed as Bullous Dermatosis. J Burn Care Res 2020; 42:569-572. [PMID: 33091119 DOI: 10.1093/jbcr/iraa184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Thermal burns can occur during seizure. This diagnosis can be difficult in case of atypical lesions, even more if the epilepsy is unknown and in case of seizures with loss of consciousness and/or an unwitnessed epileptic attack. We report two cases of cutaneous bullous lesions initially misdiagnosed as severe acute cutaneous adverse reactions (generalized bullous fixed drug eruption and Stevens-Johnson syndrome). In the two cases, the clinical aspect, necrotic evolution, and absence of obvious attributable medication allowed to revert to the diagnosis of burns due to boiling water revealing previously unknown epilepsy. For both, surgical management with skin graft was performed, and antiepileptic treatment was introduced. Facing unexplained burns, occult epilepsy should be investigated. Questioning of patient and relatives is crucial.
Collapse
Affiliation(s)
- Laura Giraud-Kerleroux
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,Department of Dermatology, Grand Hôpital de l'Est-Francilien, site Marne La Vallée, France
| | - Chloé Charpentier
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Charlotte Bernigaud
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,Faculté de santé, Université Paris Est Créteil Val de Marne, UPEC, France
| | - Nicolas Ortonne
- Faculté de santé, Université Paris Est Créteil Val de Marne, UPEC, France.,Department of Pathology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - Camille Hua
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,EA 7379 EpidermE, UPEC, Créteil, France
| | - Sophie Gaudron
- Department of Dermatology, Grand Hôpital de l'Est-Francilien, site Marne La Vallée, France
| | | | - Olivier Chosidow
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,Faculté de santé, Université Paris Est Créteil Val de Marne, UPEC, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Pierre Wolkenstein
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,Faculté de santé, Université Paris Est Créteil Val de Marne, UPEC, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,Faculté de santé, Université Paris Est Créteil Val de Marne, UPEC, France.,Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL, Créteil, France
| |
Collapse
|
95
|
Thorel D, Ingen-Housz-Oro S, Royer G, Delcampe A, Bellon N, Bodemer C, Welfringer-Morin A, Bremond-Gignac D, Robert MP, Tauber M, Malecaze F, Dereure O, Daien V, Colin A, Bernier C, Couret C, Vabres B, Tetart F, Milpied B, Cornut T, Ben Said B, Burillon C, Cordel N, Beral L, de Prost N, Wolkenstein P, Muraine M, Gueudry J. Management of ocular involvement in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: french national audit of practices, literature review, and consensus agreement. Orphanet J Rare Dis 2020; 15:259. [PMID: 32962748 PMCID: PMC7510143 DOI: 10.1186/s13023-020-01538-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2020] [Accepted: 09/09/2020] [Indexed: 12/17/2022] Open
Abstract
Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) can lead to severe ophthalmologic sequelae. The main risk factor is the severity of the initial ocular involvement. There are no recommendations for ocular management during acute phase. We conducted a national audit of current practice in the 11 sites of the French reference center for toxic bullous dermatoses and a review of the literature to establish therapeutic consensus guidelines. We sent a questionnaire on ocular management practices in SJS/ TEN during acute phase to ophthalmologists and dermatologists. The survey focused on ophthalmologist opinion, pseudomembrane removal, topical ocular treatment (i.e. corticosteroids, antibiotics, antiseptics, artificial tear eye drops, vitamin A ointment application), amniotic membrane transplantation, symblepharon ring use, and systemic corticosteroid therapy for ophthalmologic indication. Nine of 11 centers responded. All requested prompt ophthalmologist consultation. The majority performed pseudomembrane removal, used artificial tears, and vitamin A ointment (8/9, 90%). Combined antibiotic-corticosteroid or corticosteroid eye drops were used in 6 centers (67%), antibiotics alone and antiseptics in 3 centers (33%). Symblepharon ring was used in 5 centers (55%) if necessary. Amniotic membrane transplantation was never performed systematically and only according to the clinical course. Systemic corticosteroid therapy was occasionally used (3/9, 33%) and discussed on a case-by-case basis. The literature about ocular management practice in SJS/ TEN during acute phase is relatively poor. The role of specific treatments such as local or systemic corticosteroid therapy is not consensual. The use of preservatives, often present in eye drops and deleterious to the ocular surface, is to be restricted. Early amniotic membrane transplantation seems to be promising.
Collapse
Affiliation(s)
- D Thorel
- Département d'Ophtalmologie, CHU Charles Nicolle, F-76000, Rouen, France.,Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France
| | - S Ingen-Housz-Oro
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France. .,Département de Dermatologie, AP-HP, Hôpital Henri Mondor, 51 avenue du maréchal de Lattre de Tassigny, 94000, Créteil, France. .,EA7379 EpidermE, Créteil, France.
| | - G Royer
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département d'Ophtalmologie, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - A Delcampe
- Département d'Ophtalmologie, CHU Charles Nicolle, F-76000, Rouen, France.,Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France
| | - N Bellon
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département de Dermatologie, AP-HP, Hôpital Necker, Paris, France
| | - C Bodemer
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département de Dermatologie, AP-HP, Hôpital Necker, Paris, France
| | - A Welfringer-Morin
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département de Dermatologie, AP-HP, Hôpital Necker, Paris, France
| | - D Bremond-Gignac
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département d'Ophtalmologie, AP-HP, Hôpital Necker, Paris, France
| | - M P Robert
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département d'Ophtalmologie, AP-HP, Hôpital Necker, Paris, France
| | - M Tauber
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département de Dermatologie, CHU Toulouse, Toulouse, France
| | - F Malecaze
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département d'Ophtalmologie, CHU Toulouse, Toulouse, France
| | - O Dereure
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département de Dermatologie, Université de Montpellier et INSERM U1058 Pathogenèse et contrôle des infections chroniques, CHU Montpellier, Montpellier, France
| | - V Daien
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département d'Ophtalmologie, CHU Montpellier, Montpellier, France
| | - A Colin
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département de Dermatologie, AP-HP, Hôpital Henri Mondor, 51 avenue du maréchal de Lattre de Tassigny, 94000, Créteil, France
| | - C Bernier
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département de Dermatologie, CHU Nantes, Nantes, France
| | - C Couret
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département d'Ophtalmologie, CHU Nantes, Nantes, France
| | - B Vabres
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département d'Ophtalmologie, CHU Nantes, Nantes, France
| | - F Tetart
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département de Dermatologie, CHU Charles Nicolle, F-76000, Rouen, France
| | - B Milpied
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département de Dermatologie, CHU Saint-André, Bordeaux, France
| | - T Cornut
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département d'Ophtalmologie, CHU Pellegrin, Bordeaux, France
| | - B Ben Said
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département de Dermatologie, Hôpital Edouard Herriot, Lyon, France
| | - C Burillon
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département d'Ophtalmologie, Hôpital Edouard Herriot, Lyon, France
| | - N Cordel
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Unité de Dermatologie et d'Immunologie clinique, CHU Guadeloupe, Pointe-à-Pitre, Guadeloupe, France
| | - L Beral
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département d'Ophtalmologie, CHU Guadeloupe, Pointe-à-Pitre, Guadeloupe, France
| | - N de Prost
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Réanimation médicale, AP-HP, Hôpital Henri Mondor, Créteil, France
| | - P Wolkenstein
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France.,Département de Dermatologie, AP-HP, Hôpital Henri Mondor, 51 avenue du maréchal de Lattre de Tassigny, 94000, Créteil, France
| | - M Muraine
- Département d'Ophtalmologie, CHU Charles Nicolle, F-76000, Rouen, France.,Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France
| | - J Gueudry
- Département d'Ophtalmologie, CHU Charles Nicolle, F-76000, Rouen, France.,Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Créteil, France
| |
Collapse
|
96
|
Lefaucheur JP, Valeyrie-Allanore L, Ng Wing Tin S, Abgrall G, Colin A, Hajj C, de Prost N, Wolkenstein P, Ingen-Housz-Oro S, Chosidow O. Chronic pain: a long-term sequela of epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) - prevalence, clinical characteristics and risk factors. J Eur Acad Dermatol Venereol 2020; 35:188-194. [PMID: 32810314 DOI: 10.1111/jdv.16891] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Accepted: 07/13/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are associated with various sequelae. Chronic pain, one of these sequelae, has never been systematically evaluated. OBJECTIVES AND METHODS To assess the persistence of pain in a single-centre cohort of 113 consecutive patients with SJS/TEN. From this cohort, 81 patients were interviewed more than 1 year after the initial episode and included in the study. Data were collected according to standardized questionnaires. RESULTS From the 81 interviewed patients, 52 patients (64%) were painless and 29 patients (36%) were painful. Chronic pain syndrome was associated with a more severe initial acute phase of the disease (larger extent of detachment, higher SCORTEN, increased rate of admission in ICU and complications, and longer hospital stay). Pain was mainly located at the level of eyes (55%), mouth and lower limbs (38-41%), with a moderate daily intensity on average (4.7/10). The 'affective' descriptors prevailed over the 'sensory' descriptors, with the exception of burning and itching sensations. Finally, regarding provoked pain, mechanical allodynia (to brushing and pressure) was more marked than thermal allodynia. DISCUSSION The persistence of chronic pain after SJS/TEN is a common phenomenon. Sensory descriptors are consistent with sensitization of both small-diameter nerve fibres (burning and itching sensations) and large-diameter nerve fibres (mechanical allodynia), but the affective-emotional components of pain largely predominate. CONCLUSIONS Complex mechanisms lead to persistent pain as long-term sequela of SJS/TEN, among which mechanisms, psychological factors related to post-traumatic stress disorder probably play a key role.
Collapse
Affiliation(s)
- J-P Lefaucheur
- EA 4391, ENT (Excitabilité Nerveuse et Thérapeutique), Faculté de Santé de Créteil, Université Paris Est Créteil, Créteil, France.,Unité de Neurophysiologie Clinique, Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - L Valeyrie-Allanore
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Cabinet de Dermatologie, Saint-Mandé, France
| | - S Ng Wing Tin
- Unité de Neurophysiologie Clinique, Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Service de Physiologie - Explorations Fonctionnelles, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance Publique - Hôpitaux de Paris, Bobigny, France.,Inserm U1272, Université Sorbonne Paris Nord, Bobigny, France
| | - G Abgrall
- Unité de Neurophysiologie Clinique, Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - A Colin
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves, ToxiBul Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - C Hajj
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - N de Prost
- Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves, ToxiBul Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Service de Réanimation, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - P Wolkenstein
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves, ToxiBul Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - S Ingen-Housz-Oro
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves, ToxiBul Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,EA 7379 EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques), Faculté de Santé de Créteil, Université Paris-Est Créteil, Créteil, France
| | - O Chosidow
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves, ToxiBul Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| |
Collapse
|
97
|
Lefaucheur JP, Hajj C, Valeyrie-Allanore L, Colin A, Ng Wing Tin S, de Prost N, Wolkenstein P, Chosidow O, Ingen-Housz-Oro S. Involvement of small-diameter nerve fibres in long-term chronic pain after Stevens-Johnson syndrome or toxic epidermal necrolysis. A neurophysiological assessment. J Eur Acad Dermatol Venereol 2020; 35:e218-e221. [PMID: 32920914 DOI: 10.1111/jdv.16940] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- J-P Lefaucheur
- EA 4391, ENT (Excitabilité Nerveuse et Thérapeutique), Faculté de Santé de Créteil, Université Paris Est Créteil, Créteil, France.,Unité de Neurophysiologie Clinique, Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - C Hajj
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - L Valeyrie-Allanore
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Cabinet de Dermatologie, Saint-Mandé, France
| | - A Colin
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves ToxiBul, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - S Ng Wing Tin
- Unité de Neurophysiologie Clinique, Service de Physiologie - Explorations Fonctionnelles, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Service de Physiologie, Explorations Fonctionnelles et Médecine du Sport, Hôpital Avicenne, Assistance Publique - Hôpitaux de Paris, Bobigny, France
| | - N de Prost
- Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves ToxiBul, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Service de Réanimation, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - P Wolkenstein
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves ToxiBul, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - O Chosidow
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves ToxiBul, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - S Ingen-Housz-Oro
- Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,Centre de Référence des Dermatoses Bulleuses Toxiques et Toxidermies Graves ToxiBul, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Créteil, France.,EA 7379 EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques), Faculté de Santé de Créteil, Université Paris-Est Créteil, Créteil, France
| |
Collapse
|
98
|
D'Incan M, Ingen-Housz-Oro S, Beylot-Barry M, Joly P, Grange F, Quereux G, Templier I, Ram-Wolff C, Adamski H, Lambert C, Descours C. Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas. Br J Dermatol 2020; 184:356-358. [PMID: 32810288 DOI: 10.1111/bjd.19495] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Revised: 07/30/2020] [Accepted: 08/14/2020] [Indexed: 11/28/2022]
Affiliation(s)
- M D'Incan
- Department of Dermatology and Skin Oncology, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | | | - M Beylot-Barry
- Department of Dermatology, CHU de Bordeaux, Bordeaux, France
| | - P Joly
- Department of Dermatology, CHU de Rouen, Rouen, France
| | - F Grange
- Department of Dermatology, CHU de Reims, Reims, France
| | - G Quereux
- Department of Dermatology, CHU de Nantes, Nantes, France
| | - I Templier
- Department of Dermatology, CHU de Grenoble, Grenoble, France
| | - C Ram-Wolff
- Department of Dermatology, Hôpital Saint-Louis, Paris, France
| | - H Adamski
- Department of Dermatology, CHU de Rennes, Rennes, France
| | - C Lambert
- Department of Biostatistics, CHU de Clermont-Ferrand, France
| | - C Descours
- Department of Dermatology and Skin Oncology, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| |
Collapse
|
99
|
Calas A, Lheure C, Bernigaud C, Meritet JF, Sohier P, Augustin J, Isnard C, Franck N, Royer G, Ingen-Housz-Oro S, Dupin N. Adenovirus-induced Erythema Multiforme: Eye and Genital Mucosal Involvement is Specific, Whereas Oral and Cutaneous Involvement is Not. Acta Derm Venereol 2020; 100:adv00181. [PMID: 32511743 PMCID: PMC9248098 DOI: 10.2340/00015555-3547] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Affiliation(s)
- Albane Calas
- Department of Dermatology, Hôpital Cochin, APHP.CUP, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
100
|
Berot V, Bernigaud C, Ferchiou A, Ingen-Housz-Oro S, Hüe S, Ajzenberg C, Thomas S, Wieliczko-Duparc E, Billaud E, Ait-Ammar N, Ortonne N, Botterel F, Chosidow O. Extensive cutaneous and muscular mucormycosis complicating insulin pump treatment. J Eur Acad Dermatol Venereol 2020; 34:e486-e489. [PMID: 32242983 DOI: 10.1111/jdv.16406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2020] [Revised: 03/11/2020] [Accepted: 03/17/2020] [Indexed: 11/28/2022]
Affiliation(s)
- V Berot
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - C Bernigaud
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,Research Group Dynamyc, EA7380, Faculté de médecine Université Paris-Est Créteil, Ecole nationale vétérinaire d'Alfort, USC ANSES, Créteil, France
| | - A Ferchiou
- Department of Immunology, AP-HP, Henri Mondor Hospital, Créteil, France.,INSERM U955, Equipe 21, Université Paris-Est, Créteil, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - S Hüe
- Department of Immunology, AP-HP, Henri Mondor Hospital, Créteil, France.,INSERM U955, Equipe 16, Université Paris-Est, Créteil, France
| | - C Ajzenberg
- Department of Diabetology and Endocrinology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - S Thomas
- Quality and Risks Management, AP-HP, Henri Mondor Hospital, Créteil, France
| | - E Wieliczko-Duparc
- Regional Coordinator of Medical Device Surveillance, Materiovigilance et Réactovigilance Ile-de-France, AP-HP, Henri Mondor Hospital, Créteil, France
| | - E Billaud
- Department of Pharmacology, AP-HP, European Georges Pompidou Hospital, Paris, France
| | - N Ait-Ammar
- Research Group Dynamyc, EA7380, Faculté de médecine Université Paris-Est Créteil, Ecole nationale vétérinaire d'Alfort, USC ANSES, Créteil, France.,Unit of Mycology and Parasitology, Department of microbiology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - N Ortonne
- Department of Pathology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - F Botterel
- Research Group Dynamyc, EA7380, Faculté de médecine Université Paris-Est Créteil, Ecole nationale vétérinaire d'Alfort, USC ANSES, Créteil, France.,Unit of Mycology and Parasitology, Department of microbiology, AP-HP, Henri Mondor Hospital, Créteil, France
| | - O Chosidow
- Department of Dermatology, AP-HP, Henri Mondor Hospital, Créteil, France.,Research Group Dynamyc, EA7380, Faculté de médecine Université Paris-Est Créteil, Ecole nationale vétérinaire d'Alfort, USC ANSES, Créteil, France
| |
Collapse
|